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Higher dietary fat intake and alterations in fatty acid metabolism may affect cancer
development and progression. This dissertation conducted a series of studies examining
whether dietary fat intake and genetic variants in fatty acid metabolism genes have an impact
on clinical outcomes among non-Hispanic whites newly diagnosed with non-small cell lung
cancer (NSCLC). First, a cohort of 2,262 NSCLC patients was prospectively examined for
intakes of total, saturated, monounsaturated, and polyunsaturated fat in relation to overall
survival and recurrence. Dietary fat intake at diagnosis was assessed with a previously
validated food frequency questionnaire and categorized by Dietary Reference Intakes.
Multivariable Cox proportional hazard models were used to estimate adjusted hazard ratios
(HRs) with 95% confidence intervals (CIs). Neither high intake of total, nor any subtype of
fat, was associated with overall survival or recurrence for NSCLC. Analysis of stage-specific
overall survival revealed that early-stage patients with high intake of saturated fat were at
increased risk of poor survival compared to those who had intake less than the recommended
amount (HR: 1.27; 95% CI: 1.02, 1.59). However, a protective effect was observed in

advanced-stage patients who received primary chemotherapy (HR: 0.84; 95% CI: 0.71, 0.99).
This protective effect was also evident for high intake of monounsaturated fat in this same
group of patients (HR: 0.64; 95% CI: 0.43, 0.96). In the second aim, the associations between
single nucleotide polymorphisms (SNPs) in genes related to fatty acid metabolism and overall
survival and recurrence among NSCLC patients were examined by using two-stage design,
and further evaluated for differences by dietary fat intake. Among 1,593 NSCLC patients in
the discovery set, candidate SNPs associated with overall survival or recurrence were
identified, and were further validated in the replication set of 746 NSCLC patients. Four SNPs
were associated with overall survival and one SNP was associated with recurrence in both
datasets.

Functional

assessment

identified

three

variants

ACSL1:rs4862417,

CYP2C8:rs1934953, and FADS2:rs174611 to be putatively functional. Early-stage patients
with a G variant rs174611 were associated with 28% and 47% increased risk of death in the
discovery (95% CI: 1.03, 1.59) and replication sets (95% CI: 1.03, 2.08), respectively.
Monounsaturated fat intake was found to interact with rs174611 genotype in relation to overall
survival (multiplicative Pinteraction = 0.03). In summary, dietary fat intake and genetic variants
in fatty acid metabolism genes play roles in survival among NSCLC patients. The association
of dietary fat and overall survival is dependent on disease stage and treatment for NSCLC.
Genetic variants and dietary fat intake may have multiplicative effect on overall survival in
NSCLC. These findings provide evidence for potential genetically-targeted nutritional
consultation on dietary fat intake for NSCLC patients.
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CHAPTER I: BACKGROUND

Epidemiology of Lung Cancer
Lung cancer has remained the leading cause of cancer deaths for several decades across the
world (1). In 2018, a total of 1.76 million deaths from lung cancer were estimated, accounting
for approximately one in five of cancer-related deaths worldwide (2). Lung cancer comprises
a heterogeneous histology that can be divided into two major types: small cell lung cancer
(SCLC) and non-small cell lung cancer (NSCLC). SCLC accounts for 15-20% of lung cancers,
which behaves biologically aggressively and leads to poor survival (3, 4). About 80-85% of
lung cancers are NSCLC that is the most common type of lung cancer (4). NSCLC can be
further divided into three major subtypes: adenocarcinoma, squamous cell carcinoma and large
cell carcinoma. Adenocarcinoma is the most prevalent type of NSCLC, accounting for 40% of
lung cancers. Adenocarcinoma tends to grow slowly as opposed to other cell types (5). The
incidence of adenocarcinoma has surpassed that of squamous cell carcinoma during the last
several decades (6). Approximately 30% of lung cancers are squamous cell carcinoma. By
contrast, large cell carcinoma occurs in only approximately 15% of people with lung cancer,
which usually grows and spreads fast, similarly to SCLC (4). The prognosis of large cell
carcinoma is usually poorer than the other NSCLCs (7).
It has been widely known that cigarette smoking is a major cause of lung cancer (8).
Inhalation of cigarette smoke is the primary source of exposure to carcinogens among smokers.
The potential carcinogens in cigarette smoke include polycyclic aromatic hydrocarbons
(PAHs), N-nitroso compounds (NOCs), aromatic amines, and a large variety of organic and
1

inorganic chemicals (7). However, there is also a large fraction of lung cancer cases among
never smokers (9). Evidence indicates that smokers and never smokers with lung cancer may
have biological and genetics differences (10). Although smoking is a strong risk factor for all
histological types of lung cancer, squamous cell of lung cancer is the most prevalent subtype
among male smokers (11). Lung cancer in never smokers occurs more frequently among
women, and the subtype of adenocarcinoma is seen more often in never smokers and females
(10, 11). It is noteworthy to mention that lung cancer in smokers and never smokers display
distinct patterns of oncogenic aberrations. Lung cancer in never smokers tends to carry
mutations in the epidermal growth factor receptor (EGFR) as well as anaplastic lymphoma
kinase (ALK) alterations compared to smokers, whereas kirsten rat sarcoma viral oncogene
homologue (KRAS) mutations occur less frequently among never smokers (10). In addition to
cigarette smoking, there are other important environmental factors related to lung cancer,
including secondhand smoke (12), radon (13), ambient air pollution (14), and occupational
exposures (15).
Genetic factors can also come into play in the development of lung cancer. Numerous
studies observed familial aggregation of lung cancer, wherein multiple family members are
diagnosed with lung cancer (16, 17). Family members share environmental exposures and
genetic factors, both of which account for familial lung cancer. Nevertheless, individuals with
a family history of lung cancer have significantly increased risk of lung cancer than those
without such a history, and this relationship remains after adjusting for shared environmental
exposures such as cigarette smoking (17, 18).

2

Single nucleotide polymorphisms (SNPs), the most common type of DNA variation among
humans, are single base pair changes throughout the genome occurring at every 1,000
nucleotides on average (19). Single base pair alterations may alter the function or structure of
the encoded proteins, and thus have a genetic predisposition to certain diseases, including
cancer (19, 20). These SNPs usually occur within a gene or in regulatory region near a gene.
However, most SNPs have a negligible effect on health, which generally occur in the noncoding region. Candidate gene studies have been the focus prior to the era of genome-wide
association studies (GWAS). Candidate gene studies are relatively inexpensive and easy to
perform, and most of the effort focused on identifying risk variants in genes related to the
mechanism of a particular trait (21, 22). For lung cancer, this has included studies focusing on
alterations in genes related to nicotine metabolism, DNA repair, inflammation, and cell-cycle
pathways (23). Nevertheless, the results from many of these candidate gene studies have been
inconsistent (24). In contrast, a large number of genetic variants implicated in the risk of lung
cancer have been identified by GWAS. A typical GWAS uses a large sample of unrelated
individuals and thousands of different loci in the human genome to distinguish common
genetic variants for complex diseases, and focuses on the associations of SNPs with common
human diseases (25). GWAS is a discovery-driven approach, without any prior knowledge of
disease processes. The primary goal of GWAS is to discover novel genetic associations that
could develop better strategies to detect, treat and prevent diseases. Over the past decade,
GWAS has found that variants on nicotinic acetylcholine receptor subunits, telomerase, and
DNA damage response were associated with lung cancer susceptibility (26-30). Only SNPs
with p value <5×10-8 are considered statistically significant due to issues arising from multiple
3

testing and type I errors. Several SNPs that are truly but weakly associated with risk of lung
cancer may fail to be detected. In addition, earlier GWAS often focused on the effect of genetic
variants in a small number of genes on lung cancer susceptibility. The advancement of
genotyping technology greatly increases the number of genetic variants that can be examined
for association in GWAS, and began to be incorporated into pathway analysis (31). Pathwaybased GWAS has become a popular approach to investigating the relationship between groups
of genetic variants in the same biological pathway and disease. This approach substantially
reduces the multiple testing burden and makes it possible to examine the true associations
reporting lower effect size at individual genes. Pathway-based approach facilitates the
understanding of genetic susceptibility to lung cancer and is conducive to unraveling the
genomic complexity of lung cancer (32, 33).
The overall 5-year survival rate for lung cancer in the United States is only 18% (34), which
is much lower than that of other common cancers (7). Research efforts have been made to
identify prognostic factors that can be used in routine clinical practice to best take care of
patients with lung cancer. Tumor stage is considered the predominant prognostic factor in lung
cancer to guide treatment decision and to determine overall survival (35). Up to 56% of patients
who are diagnosed with localized lung cancer have survived 5-year or more, compared to 30%
and 5% for regional and distant cancers, respectively (34). Other established factors include
tumor histology, age, gender, and performance status, which can be considered alongside with
tumor stage to refine prognosis (36, 37). However, these factors remain insufficient to predict
survival in lung cancer patients (38).
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Poor survival in lung cancer can be partially explained by high prevalence of smoking (39)
and high proportion of patients with advanced stage at diagnosis (40). Recent evidence
demonstrates that smoking cancer patients limits the efficacy of cancer treatment and increases
the risk of undesired side effects (41, 42), suggesting a potential causal relationship between
smoking and adverse clinical outcomes in cancer patients (43). In addition, curative resection
of lung cancer may no longer be a treatment option for patients with advanced-stage of lung
cancer as a result of metastases. Accordingly, the implementation of smoking cessation and
screening for early detection of lung cancer have been of great interest (44, 45). The more
recent advent of low-dose computed tomography (CT) allows for more accurate detection of
lung cancer at an early stage than does standard chest radiography (46). Evidence from the
National Lung Screening Trial showed a 20% reduction in mortality from lung cancer in the
low-dose CT group compared to the standard chest radiography (47). Although great progress
has been made to decrease lung cancer mortality, long-term survival rate in lung cancer patients
has remained low (48). Therefore, there is a pressing need to identify modifiable determinants
of survival in patients with lung cancer.

Dietary Assessment Tools
Measurement of dietary exposure is an important process to understand the link between
diet and cancer. However, it is challenging to accurately assess dietary intake because of the
within and between subject variations in food consumption, and people may not accurately
report the amount or the type of food that they have eaten. Although several dietary assessment
tools are available to estimate a person’s dietary intake, the choice of tool used to assess dietary
5

intake may affect varying types and degrees of measurement error (49). Dietary assessment
can be either objective or subjective. Duplicate diet approach is a type of objective dietary
assessment which collects duplicate portion of all the foods that subjects have eaten during the
study period, and the amount of food consumed is weighted and recorded. This approach is
considered as the most precise method for estimating dietary intake because it can capture the
actual dietary intake information. One disadvantage is that the duplicate diet approach is costly
in both time and money, and thus is not suitable for large-scale studies.
Subjective dietary assessment can be performed using the three main methods: 24-hour
dietary recall, diet record, and food frequency questionnaire. The 24-hour dietary recall asks
individuals to provide the actual intake information during the previous 24-hour period. The
diet record method is similar to the 24-hour recall, but has a much longer observation period,
which is only one difference between the diet record method and 24-hour dietary recall. The
diet record method collects the actual intake information over a period, usually three to five
consecutive days. Both methods use open-ended questions to assess food consumption,
providing detailed intake information and can be easily used in different populations. The 24hour dietary recall and diet record method provide typical meal and food consumption
immediately prior to a study. Recall bias may not be a serious issue, but has a substantial
burden on the respondents. While eating behavior may change from day to day, multiple
records or recalls over several days are required to assess usual routine eating patterns.
However, it is time-consuming and expensive to collect repeated measures. On the other hand,
food frequency questionnaires (FFQ) ask the respondents to report how often and how much
food were consumed over a relatively long period of time, typically one year. This method
6

enables the assessment of habitual dietary intake rather than that of current intake. FFQ enables
researchers to perform comprehensive assessment of various nutrients and dietary components
in a relatively simple, cost-effective, and time efficient manner. The burden on the respondents
is lower and trained interviewers may not be required. Therefore, the FFQ has been widely
used in epidemiological studies. The major limitation of the FFQ is that the questionnaire
should be specifically developed for study population because diet may be influenced by
ethnicity, culture, and economic status. Additionally, FFQ is prone to recall bias since
individuals are asked to report their diet intake retrospectively for a prolonged period of time.

Dietary Intake and Lung Cancer Risk
Previous research has suggested that dietary factors may modulate lung cancer risk. The
associations between dietary factors and lung cancer risk have been extensively examined for
red meat (50), fruits and vegetables (51), but less studied for the other factors. High
consumption of red meat has been associated with increased risk of lung cancer (50). Because
of high levels of heme iron and saturated fat in red meat, the mutagenic byproducts such as
heterocyclic amines, polycyclic aromatic hydrocarbons (PAHs) and N-nitroso compounds
(NOCs) are produced when cooking at high temperatures, leading to carcinogenesis (52-54).
On the other hand, a higher intake of fruits and vegetables has been associated with decreased
risk of lung cancer (51), because fruits and vegetables contain carotenoids and other
phytochemicals that may act as antioxidants in prevention of carcinogenesis.
Dietary fat intake is an emerging research interest and also of importance because it is a
modifiable risk factor (55). Several observational studies have evaluated the role of dietary fat
7

in lung cancer risk, but the findings have remained inconclusive. The four case-control studies
from Hawaii (56), Iowa (57), and Uruguay (58, 59) observed a positive association of dietary
fat with lung cancer risk among ethnically diverse populations. Specifically, the study in
Hawaii found the effect of dietary fat on lung cancer risk among men, but not among women
(56). The odds ratio (OR) of lung cancer risk for the highest fat consumption quartile compared
with the lowest quartile among male cases of lung cancers and male persons without lung
cancer was 2.2-fold (95% confidence interval [CI], 1.3-3.7), after adjusting for age, ethnicity
and pack-years of cigarette smoking. In the Iowa study that only targeted women, the excess
risk of lung cancer was associated with fat intake (OR= 2.0; 95% confidence interval 1.3-3.1),
adjusting for age and nutrient density calories (57). Two additional case-control studies of fat
intake and lung cancer susceptibility were conducted in Uruguay. One study found that the
highest fat intake was associated with a 128% increased risk of lung adenocarcinoma (95% CI,
1.5-3.5) than the lowest fat intake with adjustments for age, residence, urban or rural status,
education attainment, body mass index (BMI), smoking status and total energy intake (58).
The other study showed a 190% increased risk of lung cancer (95% CI, 1.8-3.9) associated
with the highest fat intake after adjusting for age, residence, urban or rural status, pack-years
of cigarette smoking, total energy intake, vegetables and fruits intake, and alpha-carotene
intake (59). Nonetheless, the findings from another two case-control studies in China (60) and
Missouri (61) showed null association between fat intake and lung cancer risk. A recent metaanalysis of the above-mentioned case-control studies demonstrated that high-fat intake was
positively associated with lung cancer risk (OR= 1.64; 95% CI, 1.2-2.3) (62).
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Given that dietary assessment in case-control studies is carried out after cancer diagnosis,
recall bias may arise. To circumvent recall bias, several cohort studies with prediagnostic
dietary assessment have been conducted to examine the role of fat intake in the development
of lung cancer in the 1990s (63-68). A positive association between high consumption of fat
and elevated lung cancer risk was observed in the three cohorts including Finland (65), Norway
(67) and New York (63). However, only the result from the New York cohort was statistically
significant (63). The New York cohort demonstrated a 44% increased risk of lung cancer (95%
CI, 1.11-1.87) for the highest tertile versus the lowest tertile intake of fat only among males
after adjusting for age, education attainment, pack-years of cigarette smoking and total energy
intake. The New York cohort also observed that the effect of fat intake was confined to
squamous cell carcinomas of the lung. The two cohort studies in Finland and Norway reported
a 40-60% increased risk of lung cancer associated with the highest fat intake, but the risk was
not statistically significant (65, 67). By contrast, another three cohort studies found no evidence
for the effect of fat intake on lung cancer risk (64, 66, 68). It was anticipated that these earlier
cohort studies may not have enough statistical power of assessment for dietary intake and lung
cancer risk, since only a few cases of lung cancer would have developed during the follow-up
periods given a limited number of study participants. In 2002, a pooled analysis was conducted
of 8 prospective cohorts comprised of about half a million total participants (69). There were
3,188 incident cases of lung cancer that were identified during the follow-up periods of 6-16
years. The pooled analysis revealed that dietary fat intake was not associated with lung cancer
risk in the pooled multivariate model after adjusting for age, education attainment, BMI,
alcohol intake, total fruit and vegetable intake, energy intake and smoking status. Such a
9

conclusion had muted subsequent reports since then. In 2017, a larger pooled analysis
including 10 prospective cohorts from the United States, Europe and Asia generated attention
to address the association of dietary fat intake with lung cancer risk (70). This recent pooled
analysis looked at approximately 1.4 million participants with a median follow-up of 9.4 years.
In addition to adjusting for the empirical confounding variables, such as age, sex, smoking
status, pack-years of cigarette smoking, education attainment, obesity status, alcohol intake,
intakes of total energy and vegetables, this pooled analysis also controlled for family history
of lung cancer, race, physical activity level and menopausal status in women. After adjusting
for the above-mentioned potential confounders, it showed that the highest fat intake was
associated with a 7% increased risk of lung cancer (95% CI, 1.00-1.15). Although this study
showed a much lower risk estimate than previous studies, the large sample size of the
international cohort consortium with the prospective study design pointed out the potential
increased risk of high fat diet for the development of lung cancer.

Specific Types of Dietary Fat and Lung Cancer Risk
Fat is one of the main macronutrients, which is made up of glycerol and fatty acids. Fatty
acids play an important role in energy storage, membrane synthesis, and signaling processes
(71). Most fatty acids can be derived from either diet or synthesis by humans, except for
essential fatty acids such as linoleic acid (also known as omega-6 acid) and alpha-linolenic
acid (also known as omega-3 acid) that must be obtained from food intake. Fatty acids are long
aliphatic chain, and they may be saturated or unsaturated. The difference between saturated
and unsaturated fat lies in the number of double bonds within the fatty acid chain. Saturated
10

fat lacks double bond, while unsaturated fat has at least one double bond between the individual
carbon atoms. Specifically, unsaturated fat can be divided into three major categories:
monounsaturated, polyunsaturated and trans fat. Monounsaturated fat contains one double
bond within the fatty acid chain, polyunsaturated fat contains more than one double bonds, and
trans fat contains one or more double bonds in a trans geometric configuration.
Saturated fat is found in both animal and plant sources, but it is mainly found in animals.
Rich sources of dietary saturated fat include cheese, butter, animal fat, processed meat, palm
oil and coconut oil. It has been reported that saturated fat intake is associated with increased
risk of cardiovascular disease by increasing serum low-density lipoprotein cholesterol (LDLC) level (72). The World Health Organization (WHO) suggests that saturated fat intake should
be less than 10% of total energy intake, and individuals whose intake of saturated fat is greater
than 10% of total energy should reduce their saturated fat intake. Moreover, saturated fat has
been identified as a possible risk factor for lung cancer. The majority of case-control studies
have found a positive association between saturated fat intake and lung cancer risk (56-59).
The risk of lung cancer in subjects with the highest intake of saturated fat was 1.9 to 3-fold
higher than that of the lowest intake group. Only two case-control studies reported no
association of saturated fat intake with lung cancer (60, 61). The positive association between
saturated fat and lung cancer risk was also found in a few prospective cohort studies (63, 70),
while most other cohort studies found no positive association (66-69).
Monounsaturated fats can be derived from plant-based foods and animal products.
Specifically, monounsaturated fats from plant-based foods include olive, canola and peanut
oils, avocados, cashews, almonds, as well as pumpkin and sesame seeds. Animal products from
11

red meat and high-fat dairy are not only rich in saturated fat but also monounsaturated fat.
Monounsaturated fats, especially from plant-based foods, have been suggested to have a
beneficial effect on heart diseases (73). In contrast, the evidence for the effect of dietary
monounsaturated fat on lung cancer risk showed that high intake of monounsaturated fat is
unlikely to provide benefit (58, 59, 63, 67). The findings from epidemiological studies revealed
that high intake of monounsaturated fat was associated with a 1.4 to 2.1-fold increased risk of
lung cancer. However, some studies did not confirm the relationship between monounsaturated
fat intake and lung cancer risk (60, 69, 70). The inconsistent findings may be due to the fact
that previous studies on monounsaturated fat intake in relation to lung cancer risk did not
differentiate the sources of monounsaturated fats.
Polyunsaturated fats include omega-6 and omega-3 fatty acids that are needed for brain
function and cell growth. Polyunsaturated fats have been shown to lower the risk of heart
diseases, along with monounsaturated fats. Polyunsaturated fats can be found mostly in nuts,
plant-based oils and fatty fish. Food sources of high concentration in polyunsaturated fats
include walnuts, sunflower seeds, canola and sunflower oils, salmon and tuna. The results from
observational studies have been inconclusive in terms of association between polyunsaturated
fat and lung cancer risk. Furthermore, although the majority of cohort studies indicated no
association between polyunsaturated fat intake and lung cancer risk (63, 69, 74-76), a few
cohort studies demonstrated the potential benefit of polyunsaturated fat intake for lung cancer
(70, 77). One cohort study conducted in Japan observed that high fish consumption was
associated with an 81% reduced risk of lung cancer (95% CI, 0.08-0.46) (77). A recent pooled
analysis of cohort studies also indicated that participants who consumed high amounts of
12

polyunsaturated fats had an 8% lower risk of lung cancer than those who consumed low
amounts (95% CI, 0.87-0.98) (70). Moreover, several case-control studies reported a
significantly lower risk of lung cancer that was linked with high consumption of
polyunsaturated fats (78, 79). Nonetheless, some case-control studies displayed either no
association (58, 60, 80) or a positive association (59) between polyunsaturated fat intake and
lung cancer risk.
Dietary trans fat is mainly obtained from industrially produced food, especially in hardened
vegetable fats used for frying, baked goods, processed snack foods, and margarine. A small
amount of trans fat can also be found naturally in high-fat dairy products (such as butter and
whole milk) and meat from ruminants animals (such as cattle and sheep). Studies have

demonstrated that trans fat has an unfavorable effect on cardiovascular diseases because trans
fat increases serum LDL-C level and decreases serum high-density lipoprotein cholesterol
(HDL-C) level (81). Intake of trans fat may also be associated with cancer development
through its effects on inflammation and oxidative stress (82). On the other hand, the
relationship between trans fat intake and lung cancer risk has not been extensively investigated
in epidemiological studies, although the available evidence suggests no association between
trans fat intake and lung cancer risk (66, 83). Therefore, more studies are needed to clarify the
relationship between trans fat intake and lung cancer risk.

Dietary Intake and Survival for Lung Cancer Patients
Lung cancer patients often experience malnutrition that can reduce their survival (84, 85).
Some patients already have nutritional deficiencies when they are diagnosed with lung cancer,
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particularly for those with advanced stage or metastatic disease (86). The low blood nutrient
levels may result from unbalanced diets. Cancer can cause profound metabolic and
physiological alterations, and thus patients may consume inadequate proportions of
macronutrients (such as carbohydrates, fats and proteins) or micronutrients (such as vitamins
and minerals) (87). In addition, lung cancer patients commonly experience adverse effects of
treatment such as loss of appetite, nausea, vomiting, changes in taste or smell, pain and fatigue
(88). These symptoms may have a negative impact on appetite and food intake, leading to
alteration in nutritional status. On the other hand, adverse effects of smoking could also play a
role in low blood nutrient levels that may begin prior to cancer diagnosis (89). Smokers tend
to have a low concentration of micronutrients such as ascorbic acid (vitamin C) compared to
non-smokers. Research has identified adverse effects of smoking on changing the intake,
absorption, transport, utilization, and excretion of ascorbic acid (90).
Cancer patients are highly motivated to change their eating patterns to improve their
survival. Few epidemiological studies have been done to understand the relationships between
dietary intake and survival among lung cancer patients. In 1992, Goodman et al. conducted the
first study to assess the dietary determinants of lung cancer survival among lung cancer patients
(91). The retrospective cohort study comprised 675 patients who were newly diagnosed with
lung cancer in Hawaii. The result of this study noted that increasing consumption of vegetables
or fruits prior to cancer diagnosis was associated with a longer survival among women with
lung cancer, but not among men. The finding was consistent with investigations of dietary
intake and lung cancer risk that have shown the protective effects of vegetables and fruits
against lung cancer. Besides, one prospective cohort study conducted in the Danish population,
14

which included 353 patients with lung cancer, found a tendency towards lower risk of death
for patients with higher intake of fruits or vegetables before the diagnosis of lung cancer, but
the finding did not reach statistical significance (92). In contrast, high intake of potatoes
showed a tendency toward increased hazard of dying. A cohort study in Hong Kong comprising
1,208 patients with lung cancer found that men who consumed preserved and dried foods
frequently prior to the diagnosis of lung cancer had an increased risk of death (93).
Nevertheless, the associations between meat, fruits and vegetables consumption and lung
cancer survival were not statistically significant. This study also found that men who drank
alcohol 1-3 days per week before lung cancer diagnosis had a lower risk of death, but the
favorable effect on prognosis of lung cancer disappeared in men who drank alcohol more than
3 days per week.
Although previous studies have attempted to investigate the relationship between dietary
intake and lung cancer survival (91-93), only one of them has examined the effect of dietary
fat intake on survival among lung cancer patients to date (93). However, the study did not
differentiate what types of meat were consumed that could mask the real association for lung
cancer survival. The types of meat differ significantly in the quality of fats. Higher intake of
red meat from animal sources contain high amounts of saturated fat. Few studies have found
that higher intakes of red meats were associated with poorer cancer survival (94, 95).
Moreover, the relationships between dietary fat intake and survival in patients with breast (96),
colorectal (97), prostate (98), gastric (99) and laryngeal cancers (100) have been documented.
It is reasonable to look at how dietary fat intake influences survival and prognosis among lung
cancer patients.
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Potential Mechanisms Relating Dietary Fat to Cancer
Approximately seven decades ago, Knudson postulated that cancer occurs only when it
contains two damaged alleles, also known as “two-hit” theory of cancer causation (101). The
first “hit” occurs when individuals carry a cancer susceptibility gene or receive a somatic
mutation from cancer-causing agents. Some individuals may experience additional somatic
mutation in other normal genes, and hence cancer initiates. Cancer is the uncontrolled growth
of abnormal cells that involve uncontrolled cellular proliferation, dysregulation of apoptosis,
loss of differentiation, angiogenesis, invasion, and metastasis. Certain dietary behaviors
containing food mutagens can cause DNA damage or affect cellular control of DNA regulation
via methylation (102). The imbalance of forces regulating normal cellular functions can
contribute to increased risk of cancer. Previous observational studies have suggested an
important role of dietary fat intake in the etiology of lung cancer, and several reports indicated
a dose-response relationship between total dietary fat intake and risk of lung cancer (56-59,
62, 63, 70). As mentioned earlier, a previous study in United States reported a significant
positive association of red meats contributing to high amounts of saturated fat with lung cancer
mortality (94). Besides, several lines of evidence have demonstrated that fat intake was
associated with prognosis for breast, colorectal, prostate, gastric and laryngeal cancers (96100). Dietary fat intake should come into play in terms of the prognosis of lung cancer (103).
Although the mechanisms involving dietary fat intake with lung cancer initiation and
progression are not fully understood, a growing body of evidence indicates that dietary fat
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intake may promote cancer development and progression by altering inflammatory responses
and oxidative stress.
It is well-known that inflammation plays a critical role in tumorigenesis by supplying
important pro-growth signals to the tumor microenvironment. Increased dietary intake of
saturated fat and trans fat could induce chronic inflammation and thereby promote tumor
development. It has been consistently found that saturated fat and trans fat in diet are associated
with up-regulation of inflammatory markers, such as interleukin-6 (IL-6), C-reactive protein
(CRP) and adhesion molecules (104, 105). The mechanism of how saturated fat and trans fat
mediated inflammation is complex and poorly understood. Substantial research has explored
how saturated fat intake exacerbates inflammation. The inflammatory response appears to take
place following saturated fat intake, and could last for 4-8 hours. Moreover, it could recur after
repeated consumption of saturated fat (106). The positive association between saturated fat
intake and concentration of inflammatory markers is observed particularly in overweight
participants (107), possibly through activation of nuclear factor-kappa B (NF-kB) signaling
(105). NF-kB is a transcription factor involving in several key cellular and organismal
processes, such as immune and inflammation responses, cell survival and proliferation. NF-kB
activation is constitutively seen in many solid tumors, including lung cancer (108), either by
mutation or epigenetic mechanisms (109). The activation of NF-kB supplies tumor-promoting
cytokines to the tumor microenvironment that favors cancer initiation, progression and
metastasis (110).
Additionally, dietary intake of linoleic and alpha-linolenic acids may induce inflammation
through modulation of eicosanoids that may in turn influence tumorigenesis. It is widely
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considered that linoleic acids have a proinflammatory effect, whereas alpha-linolenic acids
have an anti-inflammatory effect. However, not all of the available evidence supports this
contention. Several studies revealed no association between linoleic and alpha-linolenic acids
intake and inflammatory markers such as IL-6 or CRP (111-113). Only one study reported an
inverse association between alpha-linolenic acids intake and IL-6 concentrations (114).
Eicosanoids are bioactive signaling lipids, which have been implicated in the inflammation
processes. Elevated levels of prostaglandin E2 (PGE2), a proinflammatory eicosanoid, are
found in several human malignancies, including lung cancer (115). The up-regulation of PGE2
could promote proliferation, migration and invasion of tumor cells, and is associated with
decreased survival among these cancer patients (116).
Notably, high-fat intake is linked to increased levels of oxidative stress (117, 118) that could
lead to tumorigenesis. Oxidative stress is an imbalance between reactive oxygen species (ROS)
and antioxidants. The accumulation of ROS not only leads to chronic inflammation, but also
increases DNA damage, thus cancer initiation (119). The ROS-induced DNA damage involves
DNA strand breaks and DNA cross-links, which induces changes in transcription and signaling
factors, replication errors and genomic instability (120). For example, p53, a transcription
factor considered guardian of the human genome which regulates several important
intracellular pathways, is frequently mutated in solid tumors, including lung cancer (121).
Mutations of TP53 gene are induced by ROS, and would lead to loss of its tumor suppression
functions (122). Therefore, mutant p53 is unable to trigger cell cycle arrest, DNA repair and
apoptosis in response to oncogenic stimuli. In addition, mutant p53 could also gain oncogenic
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functions that facilitate the energy supplies of tumor cells. As a consequence, p53 mutations
are related to rapid tumor cell proliferation and increased cell migration and invasion (123).

Genetic Variants Modify Lung Cancer Prognosis and Fatty Acid Metabolism
As detailed above, evidence from candidate gene and GWAS approaches have indicated
that several SNPs are associated with the risk of lung cancer. However, few studies have
focused on lung cancer disease prognosis. Unlike identification of susceptibility loci or genes
for the risk of lung cancer, identification of SNPs for cancer prognosis must account for
additional confounding variables in the analysis, such as clinical characteristics, histology,
treatment regimens and follow-up information. These requirements may hinder progress in the
search for identifying genetic variants as prognostic factors for lung cancer using the GWAS
approach. Even with these extra hurdles, a number of SNPs related to lung cancer survival
have been identified by GWAS, although some findings may be false positive genetic
associations. Several findings provide promising results that are reproducible in additional
studies and in different ethnic groups. For example, SNP rs1878022 in the chemokine-like
receptor 1 (CMKLR1) gene is associated with decreased overall survival in NSCLC patients
who are treated with platinum-based chemotherapy. The association between the genetic
variation and lung cancer survival was first identified and validated in non-Hispanic whites
with NSCLC, and then replicated in African Americans (124, 125).
Moreover, multiple lines of evidence from GWAS suggested that fatty acid metabolism is
modified by gene variation among healthy individuals. Specifically, SNPs in fatty acid
synthase (FASN), fatty acid desaturase 1 (FADS1), fatty acid desaturase 2 (FADS2), fatty acid
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elongase 2 (ELOVL2), fatty acid elongase 6 (ELOVL6), acyl-CoA dehydrogenase short chain
(ACADS), acyl-CoA dehydrogenase medium chain (ACADM) and acyl-CoA dehydrogenase
long chain (ACADL) have been found to be associated with alterations in fatty acid metabolism
(126-129). These genetic variants across the different genes are enzymes in de novo fatty acid
synthesis, thereby affecting both systemic and localized fatty acid metabolism.

Fatty Acid Metabolism and Cancer
The tumorigenesis process has a profound impact on the metabolic status of the cell (130,
131). Instead of anabolic and catabolic pathways that are regulated by nutrient availability in
normal cells, tumor cells grow in an uncontrolled manner even under nutrient scarcity (132).
Tumor cells alter metabolism of carbohydrates, fats and proteins to meet increased energy
demands and accumulate the metabolic needs to support cell growth and proliferation (131,
133). Previously, less research efforts have been made to investigate alterations in fat
metabolism in tumor cells, while more recently the importance of alterations in fat metabolism
is increasingly being recognized (134, 135).
There are several enzymes involved in de novo fatty acid synthesis that have been related
to tumorigenesis consisting of three stages: initiation, progression and metastasis. First, ATPcitrate lyase (ACLY) is one of the main enzymes involved in fatty acid synthesis. It has been
shown that ACLY plays a role in tumorigenesis and is highly expressed in several cancers,
including lung (136), bladder (137), colorectal (138) and glioblastoma cancers (139).
Inhibition of ACLY could promote cell apoptosis and differentiation, which is a promising
therapeutic target for cancer treatment (140). Second, acetyl-CoA carboxylases (ACACs) are
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upregulated in several cancers, which have been postulated to be a therapeutic window for
cancer. ACACA, one subtype of ACACs, is enriched in lipogenic tissues and mainly controls
fatty acid synthesis. Knockdown of ACACA by small interfering RNA (siRNA) triggers
apoptosis in prostate cancer and breast cancer cells (141, 142). With regard to lung cancer,
inhibition of ACACs expression causes detrimental effect of tumor growth in preclinical
models (143). Third, fatty acid synthase (FASN) is the most studied fatty acid enzyme with
regard to cancer (144). Overexpression of FASN is observed in patients with sarcomas (145),
endometrial (146) and colorectal (147) cancers. In addition, FASN is strongly correlated with
tumor aggressiveness in breast cancer and lung cancer cells (148, 149). Lastly, stearoyl-CoA
desaturase (SCD) is an enzyme involved in the synthesis of unsaturated fatty acids (150). SCD1
is the predominant isoform, and is ubiquitously expressed among tissues (150). SCD1 plays a
key supporting role in many cancers such as lung (151), breast (152) and prostate (153). Studies
have indicated that reduction of SCD1 in lung cancer cells contributes to a decrease in the
proliferation rate, invasiveness and survival (154, 155).

Public Health Significance
Lung cancer is a disease of great public health concern and the number of deaths still
continues to grow worldwide (1). It is widely recognized that environmental factors contribute
to tumorigenesis (130). Diet can be one important domain of environmental exposures that can
modulate a key hallmark capability of tumor cells (156). Growing evidence indicates a
plausible role of dietary fat in cancer development and progression (157). While much
scholarly attention has been paid to the association of dietary fat with breast cancer, few
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investigations have been carried out in terms of lung cancer. Several studies have looked into
the relationships between total and specific types of dietary fat and lung cancer risk, but only
one study to date has examined the link between meat intake and survival among lung cancer
patients (93). Lung cancer is a heterogeneous disease, and non-small cell lung cancer (NSCLC)
is the most common type of lung cancer. Although more treatment options are available for
NSCLC, the overall survival of patients with NSCLC remains low (158). As a result, there is
a need to better understand the effect of dietary fat intake on overall survival and recurrence
among NSCLC patients, which can provide specific dietary recommendations for NSCLC
patients in order to improve survival and prognosis.
In addition to acquiring fatty acids from dietary fat intake, fatty acids can be derived from
de novo synthesis that can be modulated by genetic variation. Previous studies have identified
that several single nucleotide polymorphisms (SNPs) across fatty acid metabolism-related
genes could affect fatty acid synthesis (126-129), and some of these genes could be potential
lung cancer biomarkers (159). Nevertheless, there is limited evidence to support the
associations between SNPs in fatty acid metabolism genes and survival and prognosis of
patients with NSCLC (160), and the study simply focused on the genetic variants in a few
genes related to fatty acid metabolism. Since fatty acids are essential for tumor cells to perform
rapid cell membrane production and intracellular signaling transduction (71), it is required to
conduct a systematic search for genetic variants in all genes involved in the fatty acid
metabolism that could be a promising biomarker to improve survival and prognosis prediction
of NSCLC.
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Research Question and Hypotheses
The purpose of this dissertation is to examine the relationships between dietary fat and
clinical outcomes among patients with NSCLC. It has been documented that fatty acids, one
component of fat, are not only energy sources and membrane constituents, but also regulate a
variety of biological activities that influence human health, including carcinogenesis and
cancer progression. The different types of fat can be consumed through foods and are
determined by the chemical structure of fatty acids. Fatty acids can also be synthesized in the
human body, which could be affected by genetic variation in fatty acid metabolism-related
genes. Therefore, this research aims to investigate the roles of dietary fat intake and single
nucleotide polymorphisms (SNPs) in fatty acid metabolism-related genes in overall survival
and recurrence among patients with NSCLC.
Hypothesis 1: Dietary fat intake is associated with clinical outcomes in NSCLC patients.
Dietary fat may promote carcinogenesis by altering oxidative stress and inflammatory
responses, thereby providing the microenvironment that favors cancer initiation, recurrence
and progression. Several epidemiologic studies have evaluated the role of dietary fat in lung
cancer risk, demonstrating that high intake of total fat is associated with an increased risk of
lung cancer. However, whether high intake of total fat and specific types of fat in diet has an
impact on overall survival and recurrence in patients with NSCLC remains unclear.
Hypothesis 2: SNPs in fatty acid metabolism-related genes are associated with clinical
outcomes in NSCLC patients.
The importance of de novo fatty acid metabolism in tumorigenesis has been confirmed.
Numerous studies have found that genetics and gene expression involving fatty acid
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metabolism can contribute to tumor cell growth and survival. In particular, SNPs in fatty acid
metabolism genes could modify fatty acid metabolism. Given the close link between fatty
acids and cancer, dysregulation of fatty acid metabolism may lead to malignancy and
increase migration and invasion of tumor cells. Nevertheless, the associations between SNPs
in fatty acid metabolism-related genes and overall survival and recurrence in NSCLC patients
have not been systematically investigated in the past.
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CHAPTER II: METHODS

Study Population and Data Collection
Study participants were accrued from a large ongoing cohort study of lung cancer at
University of Texas MD Anderson Cancer Center. All study participants had to be newlydiagnosed (< 1 year before recruitment) with histologically confirmed lung cancer prior to
treatment between 1995 and 2008. There were no recruitment restrictions on age, sex,
ethnicity, histology and stage. At study enrollment, all study participants underwent a 45minute in-person interview by trained staff. A structured questionnaire was used to collect
information on demographics, smoking status, personal medical history, physical activity, and
family history of cancer. A separate nutrition questionnaire (see below) was administered to
collect dietary information. In addition, a 40 mL peripheral blood sample was drawn at the end
of each interview. Clinical and follow-up information was abstracted from medical records by
trained staff, including date of diagnosis, clinical stage, pathologic stage, tumor grade,
treatment type, tumor recurrence, dates of recurrence, vital status, and date of last follow-up or
death.
Because non-small cell lung cancer (NSCLC) accounts for the majority of lung cancers
and the small number of cases were either Hispanic or other race/ethnic groups, the analysis
of the study participants was restricted to non-Hispanic whites with NSCLC. In the first part
of this study, participants with incomplete food frequency questionnaire, outlying or
implausible energy intakes were excluded (Figure 1). An outlying energy intake was a value
outside the interval delimited by the 25th percentile minus 1.5 times the interquartile range
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(IQR) and the 75th percentile plus 1.5 times the IQR. The values for energy intake below 500
kcal/d or above 5000 kcal/d were defined as implausible energy intakes. In the second part of
this study, participants were restricted to patients with genotyping results from either
genome-wide association study (GWAS) or OncoArray approach. This study employed a
two-phase design. Participants were divided into the discovery set and the replication set.
Patients who were included for genotyping in GWAS were in the discovery set, whereas
those who were genotyped in OncoArray were in the replication set (Figure 2). In the
discovery phase, genotype data from GWAS were used to identify genetic variants of fatty
acid metabolism genes that were associated with overall survival and recurrence among
NSCLC patients. Single nucleotide polymorphisms (SNPs) that reached statistical
significance were candidates for further validation in the replication set.
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Figure 1: Schematic of study design for the first aim
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implausible energy intakes
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27

Figure 2: Schematic of study design for the second aim

Recruited patients with lung cancer

Restricted to non-Hispanic whites
with NSCLC

Availability of genotyping results

Discovery set (n= 1,593)
To identify SNPs associated with
overall survival and recurrence

Replication set (n = 746)
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significant SNPs

Examine the significant SNP-dietary
fat intake interaction (n= 1,993)
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Dietary Assessment
A modified version of the National Cancer Institute’s Health Habits and History
Questionnaire (HHHQ) was used to assess dietary intake during the year before cancer
diagnosis. The HHHQ is a food frequency questionnaire designed to assess the role of dietary
factors in disease morbidity and mortality (161), consisting of a wide array of nutrients and
food groups. It has been shown that the HHHQ is a valid food questionnaire and has been
widely used in numerous studies in the United States (162, 163). In our modified food
frequency questionnaire, 165 food and beverage items and groups were listed, including the
major nutrients in the American diet as well as ethnic foods commonly consumed in the
Houston area. The food questionnaire asked information about the frequency (rare or no, the
number of times a day, week, month or year) and portion sizes of food and beverage items
frequently consumed (the number of pieces 1, 2, 3, or 4, and the number of cups ¼, ½, 1, or
2), and eating behaviors other than the frequency and portion size of intake of specific items,
such as food preparation methods and dining at restaurants, either in categories or in an openended manner. Based on the United States Department of Agriculture (USDA) National
Nutrient Database for Standard Reference (164) and USDA Food and Nutrient Database for
Dietary Studies (165), total energy intake and energy amount consumed for each item were
calculated.
Fatty acids are a group of lipids that are available from a variety of dietary sources. This
study collected information about the consumption of foods and beverages that were associated
with fat intake using our modified food frequency questionnaire. For example, how many times
and portion sizes of meat, poultry and fish items (beef steaks, beef roasts, pork chops or roasts,
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dinner ham, hot dogs, bacon, sausage or chorizo, chicken, tuna fish, shellfish, gravies, and
hamburgers), desserts, sweets and snacks (nachos with cheese or potato skins with topping,
potato chips, pretzels, corn chips, tortilla chips or popcorn, peanut butter, peanuts, sunflower
seeds, soy nuts, power bars, and breakfast bars or granola bars), and dairy (glasses of milk,
yogurt or frozen yogurt, cottage cheese, cream cheese, sour cream, margarine, eggs, biscuits
or muffins, and pancakes, waffles or French toast) were consumed during the year before
cancer diagnosis? Fat intake was expressed as the actual quantity of fatty acid in g per day.

Genes and SNPs selection
The schematic of fatty acid metabolism genes and SNPs selection is displayed in Figure 3.
In order to analyze genetic variants of a whole genes involved in fatty acid metabolism,
bioinformatics resources were applied. Both bioinformatics resources from Reactome
(reactome.org/) and Kyoto Encyclopedia of Genes and Genomes [(KEGG) genome.jp/kegg/]
were used to search for fatty acid metabolism genes (accessed December 19, 2018). The search
included genes involved in fatty acid biosynthesis, elongation and degradation, arachidonic
acid metabolism, alpha-linolenic and linoleic acid metabolism, glycerolipid metabolism,
glycerophospholipid metabolism, and sphingolipid metabolism. A total of 97 genes were
identified that were included in both bioinformatics resources. After excluding genes that were
not found in The University of California Santa Cruz (UCSC) Genome Browser
[genome.ucsc.edu, (n=3)], 94 genes were reported to be associated with fatty acid metabolism.
A total of 691 SNPs mapped to 10 kb upstream or 10 kb downstream of these 94 fatty acid
metabolism genes were included in the discovery set (see Appendix A). rAggr (raggr.usc.edu/)
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was used to identify proxy linked SNPs as substitutes for those SNPs that were not directly
genotyped in the replication set. The 1000 Genomes Phase III database was used to identify
the linked SNPs that were in linkage disequilibrium with minor allele frequency at least 1%
and r2 of 80% or higher among European ancestry.
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Figure 3: Schematic of genes and SNPs selection
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Genotyping and Quality Control
DNA for each patient was isolated from peripheral whole blood using the QIAamp DNA
extraction kit (QIAGEN, Valencia, CA). In the discovery set, genotyping was previously
performed using the HumanHap 300k and HumanHap 660k BeadChips (Illumina, San Diego,
CA) and analyzed using BeadStudio software (Illumina). In the replication set, Infinium
Oncoarray-500K BeadChip on the iScan system (Illumina) was previously used for genotyping
and the array data were analyzed using GenomeStudio software (Illumina). All genotypes were
performed according to the manufacturers’ instructions. All individuals had a call rate of 90%
or higher and a minor allele frequency at least 1%.

Power Calculations
Since this study used existing data, the sample size was fixed. The detectable alternative
was the true hazard ratios of overall survival in the exposed group relative to that in the nonexposed group. Specifically, the detectable alternative was detected with a specified power
given the type I error probability, the number of sample size for exposed group, the ratio of
non-exposed group to exposed group, and median survival time on the non-exposed group.
The detectable alternative was calculated individually for hypothesis 1 and hypothesis 2. In
both hypotheses, an 80% probability of correctly rejecting the null hypothesis was set and a
recruitment period of 1 year was chosen after which a subsequent 5-year period was allowed
for follow-up.
In hypothesis 1, the study had 2,262 patients with NSCLC. To simplify the calculation of
the detectable alternative, fat intake was considered in binary categories using median intake
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of fat as a cutoff point. Accordingly, 1,131 patients had low fat intake with a median survival
time of 2.5 years. Under this assumption, the detected true hazard ratios of failure for patients
with high fat intake relative to those with low fat intake were 0.88 or 1.14 with a power of 0.8
and a two-tailed significance level of 0.05 (Figure 4).

Figure 4: A plot of detectable alternative hazard ratio for the first aim
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In hypothesis 2, the study had 2,339 patients with NSCLC whose peripheral blood samples
were genotyped using either GWAS or the OncoArray approach. Assuming that a SNP relative
to allelic frequency for the risk allele is 10%, 234 patients carried the risk allele and 2,105
patients did not have the risk allele. The median survival time for those who carried genotype
without the risk allele was 2.5 years. Under this context, the detected true hazard ratios of
failure for patients with the risk allele relative to those with the risk allele were 0.77 or 1.32
with a power of 0.8 and a two-tailed significance level of 0.01. A plot of detectable alternative
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hazard ratios of overall survival under the risk allele frequency of 5%, 10%, 20%, 30% and
40% is shown in Figure 5.

Figure 5: A plot of detectable alternative hazard ratio for the second aim

Statistical Analysis
All analyses were performed with Stata (College Station, TX), and 2-sided p<0.05 was
considered statistically significant. In the first part of this study, the dietary intake was energyadjusted by using the nutrient density method prior to further analysis (166). Intakes of total
fat, saturated fat, monounsaturated fat and polyunsaturated fat in diet were categorized
according to the Dietary Reference Intakes (DRIs). To determine whether demographic and
behavioral characteristics lead to different amounts of fat intake in patients with NSCLC, the
ANOVA test and chi-square test were used to compare the differences. The Cox proportional
hazards model was performed to calculate the hazard ratios (HRs) and 95% confidence
intervals for the associations between total fat and specific types of fat in diet and clinical
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outcomes among NSCLC patients. Person-time was calculated individually for overall survival
and disease recurrence. Overall survival was defined as the period from the date of diagnosis
to the date of death from any cause, or the last follow-up, whichever came first. Disease
recurrence was defined as the date of diagnosis to first recurrence, or the date of the last followup, depending on which date came first. Recurrence was defined as tumor growth in adjacent
to the planning target volume or surgical resection in the ipsilateral hilum or mediastinum, or
new sites of involvement in lymph nodes or distant organ after curative resection. The
multivariable Cox model was adjusted for potential confounders based on a priori knowledge,
such as age at cancer diagnosis, sex, education attainment, BMI, smoking status, clinical stage,
pathology, and total energy intake.
In the second part of this study, a two-phase design was employed. First, the associations
between SNPs in fatty acid metabolism genes and overall survival and recurrence among
NSCLC patients was examined in the discovery set. SNPs with significant associations from
the discovery set was examined whether they had consistent associations and reach statistical
significance in the replication set. The comparison of selected characteristics in the discovery
and replication sets was performed using the chi-square test for categorical variables and
Student t test for continuous variables. Person time was calculated individually for overall
survival and recurrence from the date of study enrollment to the date of death/recurrence, or
the last follow-up, depending on which date came first. The Cox proportional hazards model
with the estimates of HRs and 95% confidence intervals were employed to assess the
associations between SNPs in fatty acid metabolism genes and clinical outcomes for each
phase among patients with NSCLC. The multivariable Cox proportional hazards model with
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adjustment for age at diagnosis, sex, smoking status, clinical stage, performance status, and
treatment regimen were estimated in both sets. All genetic models of inheritance including the
dominant, recessive and additive models were taken into consideration in the assessment. The
genetic model with the smallest p value is considered as the best-fitting model. Q value was
used to control the false discovery rate. The significant SNPs were selected if the SNP had p
value < 0.05 and Q value < 0.20 in the discovery set, and p value remained less than 0.05 in
the replication set as well as consistent associations with overall survival or recurrence in both
discovery and replication sets. We conducted functional characterization of the significant
SNPs that were associated with clinical outcomes among patients with NSCLC. Finally, we
examined the associations of the significant SNPs in fatty acid metabolism genes and dietary
fat intake with overall survival and lung cancer recurrence.

Human Subjects Considerations
The data set was comprised of data collected by at the University of Texas MD Anderson
Cancer Center. All study participants provided written informed consent prior to participating
in the study. The study has been approved by the University of Texas MD Anderson Cancer
Center Institutional Review Board. All identifying variables were removed and only deidentified patient data were provided to the researcher. No risk of identification to study
participants nor any further contact with study participants occurred during the conduct of this
study. The dataset was stored on the University of Texas MD Anderson Cancer Center server
with secure firewalls and accessed using secure passwords. This study has been granted exempt
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status by the University of Texas Health Science Center Committee for Protection of Human
Subjects (study number: HSC-SPH-19-0085, reference number: 183036) (see Appendix B).
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CHAPTER III: JOURNAL ARTICLE 1

Title of Journal Article: Is Dietary Fat Intake Associated with Overall Survival and
Recurrence in Non-small Cell Lung Cancer? An Evidence-based Cohort Study
Name of Journal Proposed for Article Submission: The American Journal of Clinical
Nutrition

Abstract
Higher dietary fat intake is associated with increased risk of lung cancer. It remains unclear
whether total and subtypes of dietary fat intake have an impact on prognosis among patients
with non-small cell lung cancer (NSCLC). We prospectively examined intakes of total,
saturated, monounsaturated, and polyunsaturated fat in relation to overall survival and
recurrence in NSCLC. In a cohort of 2,262 patients newly diagnosed with NSCLC, dietary fat
intake at diagnosis was assessed with a previously validated food frequency questionnaire and
categorized by Dietary Reference Intakes. During median follow-up of 23 months, we
observed 1,594 deaths and 276 recurrences. Multivariable Cox proportional hazard models
were used to estimate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs).
Neither high intake of total, nor any subtype of fat, was associated with overall survival or
recurrence for NSCLC. Analysis of stage-specific overall survival revealed that early-stage
patients with high intake of saturated fat were at increased risk of death compared to those who
had intake less than the recommended amount (HR: 1.27; 95% CI: 1.02, 1.59; P = 0.03).
However, a protective effect was observed in advanced-stage patients who received primary
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chemotherapy (HR: 0.84; 95% CI: 0.71, 0.99; P = 0.04). This protective effect was also showed
for high intake of monounsaturated fat in this same group of patients (HR: 0.64; 95% CI: 0.43,
0.96; P = 0.03). The association of dietary fat and overall survival is dependent on disease
stage and treatment for NSCLC, which suggest that high intake of saturated fat may be harmful
for early-stage patients, and sufficient amounts of saturated and monounsaturated fat may have
survival benefits for advanced-stage patients who receive primary chemotherapy. These
findings provide evidence for nutritional consultation on fat intake for NSCLC patients.

Keywords: dietary factor, fat, total fat, saturated fat, monounsaturated fat, polyunsaturated fat,
lung cancer, non-small cell lung cancer, recurrence, survival, clinical outcome
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Introduction
Lung cancer is the leading cause of cancer death in the world (1). Up to 56% of patients who
are diagnosed with early-stage lung cancer have survived for 5 years or more, compared to
30% and 5% for those with locally advanced and advanced cancers, respectively (2). Of these
patients, non-small cell lung cancer (NSCLC) is the most common type of lung cancer (3).
Nearly 70% of patients with advanced-stage NSCLC at the time of diagnosis undergo
chemotherapy, often combined with radiation therapy (3). Surgical resection remains the
optimal treatment for patients with early-stage NSCLC, but 30% to 70% of patients with
NSCLC develop recurrent lesions after surgical resection (4). Survival after lung cancer
diagnosis greatly depends on tumor stage, and other factors, including tumor histology, age at
diagnosis, gender, and performance status (5) which are non-modifiable. Due to a high
recurrence rate and low survival rate for lung cancer, there is increasing interest in identifying
modifiable risk factors, particularly dietary factors, which may affect lung cancer development
and survival.
It has been suggested that dietary fat plays an important role in cancer development and
progression (6), and several studies have investigated the link between dietary fat and risk of
lung cancer with inconsistent findings (7-13). Case-control studies have shown that high-fat
intake was associated with a moderate increased risk of lung cancer (7-10). Yet the findings
from small-scale cohort studies have been null (11, 12). A recent pooled analysis using
prospective cohorts from the United States, Europe, and Asia with 1.4 million participants
suggested a potential increased risk of high fat diet for the development of lung cancer (13).
However, there has been very little epidemiologic research on the association between fat
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intake and survival for lung cancer patients. To the best of our knowledge, only one study
examined this association but showed no evidence for overall survival from lung cancer
patients with higher intakes of meats (14). Meat is one kind of dietary source containing various
types of fatty acids. Different types of fatty acids are available from a wide variety of foods.
This is the first study to prospectively investigate how intakes of specific types of fat as
nutrients affect overall survival and risk of recurrence among a large cohort of NSCLC
patients.

Methods
Patients and data collection
Study participants were accrued from a large ongoing cohort study of lung cancer at
University of Texas MD Anderson Cancer Center. All study participants were newlydiagnosed (< 1 year before recruitment) with histologically confirmed lung cancer treated
between 1995 and 2008. There were no recruitment restrictions on age, sex, ethnicity,
histology, and stage. Because NSCLC accounts for the majority of lung cancers diagnosed and
the limited number of cases from Hispanic or other ethnic groups, study participants for the
present study were restricted to non-Hispanic whites with NSCLC.
At study enrollment, all study participants underwent a 45-minute in-person interview by
trained staff. A structured questionnaire was used to collect information on demographic
characteristics, smoking status, personal medical history, physical activity, and family history
of cancer. Clinical and follow-up information was abstracted from medical records by trained
staff, including date of diagnosis, clinical stage, pathologic stage, tumor grade, treatment type,
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tumor recurrence, dates of recurrence, vital status, and date of last follow-up or death.
Recurrence was defined as tumor recurring locally, regionally, and at distant metastasis sites
after curative resection. Patients with clinical stages I and II were identified as early-stage
NSCLC, and those with stages III and IV were classified as advanced-stage NSCLC. Each
participant enrolled in this study provided written informed consents, and the study was
approved by Institutional Review Board of The University of Texas MD Anderson Cancer
Center.

Dietary assessment
During the in person interview, dietary intake during the year prior to NSCLC diagnosis
was measured with a modified version of the National Cancer Institute’s Health Habits and
History Questionnaire that was designed to capture habitual dietary intake. This food frequency
questionnaire (FFQ) was previously validated to provide reliable assessments of nutrients and
dietary components across various populations (15, 16). The details about our dietary
assessment have been previously described (17, 18). Briefly, our modified FFQ consisted of
165 food and beverage items and groups, and participants were asked information about the
frequency and portion sizes of food and beverage items frequently consumed. From the dietary
information obtained in the FFQ, the United States Department of Agriculture (USDA)
National Nutrient Database for Standard Reference (19) and USDA Food and Nutrient
Database for Dietary Studies (20) were used to determine the energy content and grams
consumed per day for each food item. The caloric values of all food items consumed by the
individuals were summed to calculate daily total energy intake. For those participants with
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incomplete answers to the food frequency questionnaire, both outlying and implausible energy
intakes were excluded. An outlying energy intake was a value that lied outside the interval
delimited by the 25th percentile minus 1.5 times the interquartile range (IQR) and the 75th
percentile plus 1.5 times the IQR. The values for energy intake below 500 kcal/d or above
5,000 kcal/d were defined as implausible energy intakes.
Since fatty acids are a group of lipids that are available from a variety of dietary sources,
fat from red meat, processed meats, dairy products, fish and shellfish, desserts, and snacks
were included in this study. Daily fat intakes were calculated by multiplying the fat content of
each food item of the specific portion size by the frequency of consumption, and then were
summed and expressed as the quantity of specific fatty acid in grams per day. Energy-adjusted
dietary intakes were obtained by nutrient density method on intakes of total, saturated,
monounsaturated and polyunsaturated fat. They were calculated by the percentage of calorie
intakes from total and specific types of fat over total energy intake. Based on the Dietary
Reference Intakes (DRIs), the recommended daily intake is 20-35% for fat, 6-10% for saturated
fat, 10-15% for monounsaturated fat, and 5-10% for polyunsaturated fat (21). High intakes of
total and specific types of fat were defined as the percentage of fat intakes being greater than
the recommended intakes, whereas low intakes were the percentage of fat intakes below the
recommended amounts.

Statistical analysis
Dietary intakes of total, saturated, monounsaturated, and polyunsaturated fat were energyadjusted prior to further analysis (22), and then were classified into three categories based on
44

DRIs for fat. Chi-square tests were used to compare the proportion fat intake by different
groups for categorical variables, and the ANOVA test was used to compare the differences
between the means of different groups for continuous variables. Analyses of the associations
between dietary fat and covariates with clinical outcomes among NSCLC patients were
conducted by using Cox proportional hazards models. Person-time was calculated individually
for overall survival and disease recurrence. Overall survival was defined as the period from the
date of diagnosis to the date of death from any cause, or the last follow-up, whichever came
first. Time to recurrence was defined as the date of diagnosis to first recurrence, or the date of
the last follow-up among early-stage patients, depending on which date came first. Because of
few patients with low fat intake prior to cancer diagnosis, we combined low and recommended
categories into one category in multivariable analysis. The multivariable Cox model estimated
hazard ratios (HRs) and 95% confidence intervals (CIs) adjusting for potential confounders
based on a priori knowledge, including age at cancer diagnosis, sex, body mass index (BMI)
at diagnosis, smoking status, clinical stage, tumor grade, pathology, and cancer treatment. In
addition, analyses were conducted stratified by patients diagnosed with early-stage and
advanced-stage NSCLC as well as by smoking status, BMI, and cancer treatment type. All
analyses were performed with Stata (College Station, TX), and 2-sided p value <0.05 was
considered statistically significant.
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Results
Host characteristics of NSCLC patients
The distribution of fat intake of the 2,262 NSCLC patients is presented in Figure 1. More
than two-thirds of patients met the recommended intakes of total, monounsaturated, and
polyunsaturated fat, whereas 62% of patients exceeded the recommendations for saturated fat.
Overall, study participants had a higher proportion of current or former smokers, lower BMI,
advanced clinical stage, poorly differentiated tumors, and adenocarcinomas (Table 1).
Patients with high intakes of total, saturated, or monounsaturated fat were more likely to be
younger at cancer diagnosis, male, current smokers and obese (Table 1 and Supplemental
Tables 1-3). In contrast, patients with high intake of polyunsaturated fat were more likely to
be female. There were no significant differences between the three groups of dietary fat intake
(low, recommended, and high) and other demographic, behavioral, and clinical characteristics,
or cancer treatment, except that patients with chemoradiation therapy had a higher proportion
of low total fat intake.

Dietary fat intake and risk of overall survival and recurrence
After a median follow-up of 23 months, 1,594 patients died and 276 tumor recurrences were
recorded. Table 2 shows the multivariable-adjusted associations of intakes of total, saturated,
monounsaturated, and polyunsaturated fat with risk of overall survival and recurrence. The
associations between fat intake and overall survival and recurrence were not significant among
NSCLC patients. The risk of overall survival by fat intake was further stratified by cancer
stage. Compared to early-stage patients with recommended or lower intake of saturated fat,
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those with high intake of saturated fat had a 27% (HR: 1.27; CI: 1.02, 1.59) increased risk of
death (Table 2). This unfavorable effect on survival was slightly increased among ever smokers
(HR: 1.31; CI: 1.03, 1.67), and the association was stronger among obese patients who had
more than double the risk of death (HR: 2.06; CI: 1.16, 3.63; Table 3). Moreover, high intake
of saturated fat was suggestive of an increased risk of death among early-stage patients who
received surgery only (HR: 1.25; CI: 0.91, 1.72) and combined surgery and chemotherapy
(HR: 1.32; CI: 0.95, 1.84) (Table 4). In contrast, although a direct relationship between fat
intake and survival was not observed for advanced-stage patients, weight- and treatmentspecific effects were observed with high fat intake on overall survival that was in the opposite
direction than that shown for early-stage patients. A favorable effect on overall survival was
observed in overweight patients with advanced-stage NSCLC who had high intake of
monounsaturated fat, with a 47% (HR: 0.53; CI: 0.29, 0.97) lower risk of death (Table 3). In
advanced-stage patients receiving primary chemotherapy, high intake of saturated or
monounsaturated fat was associated with a 16% (HR: 0.84; CI: 0.71, 0.99) and 36% (HR: 0.64;
CI: 0.43, 0.96) decreased risk of death, respectively (Table 4). Findings for all other stratified
analyses by stage, smoking status, BMI, and treatment type were null.

Discussion
This prospective cohort study showed no evidence for an association between intakes of
total, saturated, monounsaturated, and polyunsaturated fat and overall survival and recurrence
in NSCLC patients when patients who were diagnosed with early-stage and advanced-stage
were pooled together. Nonetheless, we observed that high intake of saturated fat was associated
47

with poor overall survival in patients with early-stage NSCLC, whereas patients who had
advanced cancer and received primary chemotherapy had improved overall survival. This
favorable effect on survival was also identified for monounsaturated fat intake in this same
subgroup.
The concerns over dietary fat intake and lung cancer have focused on the risk rather than
survival. There has been limited research investigating the effect of dietary fat intake on lung
cancer survival. Even though saturated fat has been suggested to play a role in lung cancer
development, epidemiologic evidence for the association is inconsistent. Individual studies
have shown positive and null association of saturated fat and risk of lung cancer (7-11). The
findings from a recent pooled analysis of previous studies showed that the highest consumption
of saturated fats was associated with a 14% increased risk of lung cancer (13). Additionally,
previous nationally representative studies in United States reported a significant positive
association of red meats contributing to high amounts of saturated fat with lung cancer
mortality (94, 95). Nevertheless, a cohort study in China showed no significant association
between high meat intake and overall survival in lung cancer patients (14). Different types of
meat contain varying concentration of fatty acids. Because the study did not specify the types
of meat consumed, it could actually hide a real association between meat intake and survival
in lung cancer patients. The relationship between high intake of saturated fat and worse
survival in patients with breast (23, 24) and prostate cancers (25) has been documented in the
United States. Similar to previous studies in other cancer sites, we found a poor overall survival
in early-stage NSCLC patients with high intake of saturated fat that exceeded 10% of total
energy intake. In addition, the effect of high saturated fat intake on overall survival was more
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evident among former and current smokers. It has been known that smoking at the time of
diagnosis is an important predictor of poor outcome in patients with early-stage NSCLC (26,
27). Cigarette smoking contains chemical carcinogens which may cause lung carcinogenesis
and recurrence (28). Although the mechanisms of how saturated fat intake leads to lung cancer
initiation and progression are not fully understood, a growing body of evidence indicates that
increased saturated fat may promote cancer development and progression by altering
inflammatory responses and oxidative stress (29). It is likely that the association between poor
survival and high intake of saturated fat may be exaggerated by smoking.
Nevertheless, we observed a non-significant impact of improvement in overall survival
among advanced-stage NSCLC patients with high intakes of saturated fat. The role of dietary
fat in cancer prognosis is likely to be a complex association, depending on the stage of cancer.
In a cohort of Swedish men with prostate cancer, greater intake of saturated fat was associated
with increased risk of prostate cancer death, particularly among patients with localized disease,
but no association was observed among those with advanced disease (30). Besides, our findings
seemed to suggest that the role of saturated fat intake depends on disease stage and treatment
for NSCLC. We found a significant overall survival improvement for high intakes of saturated
fat among advanced-stage patients who received primary chemotherapy, but high intake of
saturated fat among early-stage patients was associated with worse overall survival. The excess
fat in diet have different effects on survival varying by stage of cancer. Among patients with
early-stage cancer, excess fat intake may accumulate energy stored in adipose tissue resulting
in chronic inflammation (31). As a consequence, proliferation of blood vessels may facilitate
tumor cell growth and progression (32). By contrast, among patients with advanced-stage
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cancer, excess adipose tissue leads to a better longevity compared to normal or underfed
patients because excess adipose tissue may provide nutritional reserve to counterattack the
damage made by treatment for advanced cancer (33).
Diet high in monounsaturated fat has been suggested to replace saturated fat due to
beneficial effects on heart diseases (34), whereas previous studies have reported no association
and a positive association of monounsaturated fat intake with risk of lung cancer (9-11, 13, 35,
36). The effect of monounsaturated fat on risk of lung cancer does not yield a similar
association for survival in lung cancer patients. Although the association between
monounsaturated fat and survival has not been examined in lung cancer patients, there are
many studies looking at the role of monounsaturated fat in other cancer sites, including breast
(24), prostate (25) and stomach (37). These studies showed that higher monounsaturated fat
intake was neither associated with all-cause nor cancer-specific mortality, although the
protective association was observed for prostate and gastric cancers, and the detrimental
association was reported for breast cancer. Our study found that advanced-stage patients who
had high intake of monounsaturated fat and received primary chemotherapy had a lower risk
of death. Previous research indicated that monounsaturated fat intake has anti-inflammatory
properties and thus may suppress tumorigenesis (38), which might explain the improvement in
survival for patients with high intake of monounsaturated fat. Further research is needed to
confirm the protective effect of high intake of monounsaturated fat for patients with advancedstage NSCLC.
In addition, a greater magnitude of improved survival for high intake of monounsaturated
fat that was more than 15% of total energy intake was found in overweight patients who were
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diagnosed with advanced-stage, but was not observed in obese patients. Excess weight has
been linked to greater mortality of various cancers, including gastrointestinal, prostate, and
breast cancers (39). However, it has been suggested that increased BMI in patients with
advanced-stage lung cancer conferred favorable survival (40, 41), and early-stage patients with
a higher BMI demonstrated a significant improvement of overall survival (42), both of which
were in line with our findings. Our study observed a poor overall survival for the influence of
high intake of saturated fat among early-stage patients with obesity. It is possible that excess
weight has different effects on overall survival varying by stage of cancer. Similar to excess
fat intake in early-stage patients, excess weight increases the storage of energy in adipose tissue
and alters metabolic and inflammatory characteristics that facilitate the microenvironment
favoring tumor initiation and progression. Patients with advanced-stage cancer may benefit
from the metabolic reserves of body fat to withstand treatments (33).
There are several strengths of this study. On the one hand, we prospectively explored the
relations between total fat and subtypes of fat intake at diagnosis and clinical outcomes of
NSCLC patients, and moreover examined the effects of fat intake under different disease
stages, treatments, BMI and smoking status. On the other hand, this study used a previously
validated FFQ to collect food intake, and was able to adjust for potential confounding factors
to minimize the possibility of confounded associations. There are also several limitations of
this study. First, the dietary information was based on self-reported data, and study participants
were asked to recall what they had eaten 1 year prior to cancer diagnosis. It is likely that a
person may be unable to precisely recall and answer the habitual food that he/she actually
consumed over the past year, resulting in measurement errors in dietary data. Nevertheless, the
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measurement errors tend to be non-differential of clinical outcomes. Second, study participants
were limited to non-Hispanic whites, and thus the study results may not be directly
generalizable to the other ethnic groups. Third, although the sample size of this study was
large, the number of patients with low fat intake was relatively small, providing limited
statistical power. Therefore, we combined low fat intake with recommended fat intake to
evaluate the effects of dietary fat intake on clinical outcomes by comparing patients with high
fat intake with those who consumed the least amounts. Besides, only a small proportion of
patients consumed high polyunsaturated fat and developed recurrent disease, which indicated
a lower precision and statistical power. Lastly, despite this study took potential epidemiologic
and clinical factors into consideration for adjustment in the analysis, the possibility of
uncontrolled confounding factors could not be completely excluded. Although this study has
the above-mentioned limitations, the findings of this study may fill a gap of knowledge about
dietary fat and clinical outcomes in patients with NSCLC.
To sum up, our results indicate that the relationship between dietary fat intake and overall
survival among NSCLC seems to depend on the subtypes of fat and clinical stage. We
observed a poor overall survival for early-stage NSCLC patients with high intake of saturated
fat, but did not find similar patterns for total fat and other subtypes of fat. Besides, high
intakes of saturated and monounsaturated fat were associated with improved overall survival
among advanced-stage NSCLC patients who received primary chemotherapy. However,
there were no consistent associations between fat intake and disease recurrence. Our study
suggests that early-stage NSCLC patients may need to reduce consumption of saturated fat,
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and those who have advanced-stage and receive primary chemotherapy may need to get
enough fat intake.
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Table 1: Characteristics of NSCLC patients by total fat intake

Characteristics
Age at diagnosis, year
Sex
Men
Women
Education
High school or less
Some college
Complete college or
greater
Smoking status Never
Former
Current
BMI, kg/m2
< 25
25-30
> 30
Total energy, kcal/d
Clinical stage I and II
III and IV
Grade
Well differentiated
Moderately differentiated
Poorly differentiated
Undifferentiated
Unknown
Pathology
Adenocarcinoma
Squamous cell
Large cell
Others
Surgery
No
Yes
Radiation
No
Yes
Chemotherapy No
Yes
Chemoradiation No
Yes

All
(n = 2,262)
63.0 + 10.84
1161 (51.3)
1101 (48.7)
850 (37.6)
741 (32.8)
667 (29.5)

Total fat intake1, n (%)2
Low
Recommended
High
(n = 53)
(n = 1,402)
(n = 807)
64.2 + 11.6
63.3 + 11.0
62.4 + 10.4
29 (54.7)
689 (49.1)
443 (54.9)
24 (45.3)
713 (50.9)
364 (45.1)
21 (39.6)
488 (34.9)
341 (42.4)
18 (34.0)
470 (33.6)
253 (31.4)
14 (26.4)

399 (17.6)
1033 (45.7)
830 (36.7)
940 (41.6)
776 (34.3)
546 (24.1)
2005.2 + 719.5
780 (34.5)
1392 (61.5)
154 ( 6.8)
509 (22.5)
934 (41.3)
23 ( 1.0)
642 (28.4)
1276 (56.4)
538 (23.8)
313 (13.8)
135 ( 6.0)
1382 (61.1)
880 (38.9)
1750 (77.4)
512 (22.6)
1174 (51.9)
1088 (48.1)
1892 (83.6)
370 (16.4)

1

3 ( 5.7)
32 (60.4)
18 (34.0)
21 (39.6)
17 (32.1)
15 (28.3)
1935.4 + 847.8
17 (32.1)
36 (67.9)
5 ( 9.4)
8 (15.1)
24 (45.3)
0
16 (30.2)
34 (64.2)
10 (18.9)
6 (11.3)
3 ( 5.7)
32 (60.4)
21 (39.6)
44 (83.0)
9 (17.0)
21 (39.6)
32 (60.4)
21 (39.6)
32 (60.4)

442 (31.6)
286 (20.4)
653 (46.6)
463 (33.0)
621 (44.3)
479 (34.2)
302 (21.5)
1975.7 + 735.4
484 (35.9)
866 (64.1)
101 ( 7.2)
313 (22.3)
574 (40.9)
9 ( 0.6)
405 (28.9)
827 (59.0)
309 (22.0)
180 (12.8)
86 ( 6.1)
848 (60.5)
554 (39.5)
1083 (77.2)
319 (22.8)
716 (51.1)
686 (48.9)
716 (51.1)
686 (48.9)

211 (26.2)
110 (13.6)
348 (43.1)
349 (43.2)
298 (36.9)
280 (34.7)
229 (28.4)
2061.2 + 678.9
279 (36.3)
490 (63.7)
48 ( 5.9)
188 (23.3)
336 (41.6)
14 ( 1.7)
221 (27.4)
415 (51.4)
219 (27.1)
127 (15.7)
46 ( 5.7)
502 (62.2)
305 (37.8)
623 (77.2)
184 (22.8)
437 (54.2)
370 (45.8)
437 (54.2)
370 (45.8)

Fat intake was energy-adjusted by using the nutrient density method. Low (< 20 % kcal),
recommended (20-35 % kcal) and high (> 35 % kcal).
2
Numbers may not add up to the total because of missing data.
3
Derived by using chi-square test for categorical variables and ANOVA for continuous variables.
4
Mean + SD (all such values).
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p value3
0.03
0.03

0.009

< 0.0001

0.002
0.0002
0.82

0.23

0.02
0.72
0.61
0.07
0.02

Table 2: Risk of overall survival and recurrence by total and specific types of dietary fat intake among NSCLC patients
Overall survival
1

All participants

3

Total fat

Saturated fat4
Monounsaturated fat5
Polyunsaturated fat6
Early-stage

Total fat3
Saturated fat4
5

Monounsaturated fat
Polyunsaturated fat6
Advanced-stage

Total fat3
Saturated fat4
Monounsaturated fat5
Polyunsaturated fat6

Dietary fat intake
Recommended or lower
High
Recommended or lower
High
Recommended or lower
High
Recommended or lower
High
Recommended or lower
High
Recommended or lower
High
Recommended or lower
High
Recommended or lower
High
Recommended or lower
High
Recommended or lower
High
Recommended or lower
High
Recommended or lower
High

Events/ total
1041/1455
553/807
597/870
997/1395
1015/1570
64/114
1061/1646
20/37
254/501
123/279
133/300
242/477
242/569
14/40
253/589
4/15
749/902
398/490
446/542
703/854
744/953
45/69
776/1006
14/20

1

2

HR (95% CI)
Reference
0.95 (0.86, 1.06)
Reference
1.03 (0.93, 1.14)
Reference
0.86 (0.66, 1.11)
Reference
0.78 (0.50, 1.23)
Reference
0.92 (0.73, 1.15)
Reference
1.27 (1.02, 1.59)
Reference
0.93 (0.54, 1.62)
Reference
0.76 (0.27, 2.10)
Reference
0.96 (0.85, 1.09)
Reference
0.95 (0.84, 1.07)
Reference
0.78 (0.58, 1.07)
Reference
0.78 (0.45, 1.34)

Recurrence
p value
0.35
0.58
0.23
0.29
0.47
0.035
0.80
0.59
0.54
0.40
0.12
0.37

Fat intake was energy-adjusted by using the nutrient density method.
Multivariable model adjusted for age, gender, BMI, smoking status, stage, grade, pathology, and treatment.
3
Recommended or lower (< 35 % kcal) and high (> 35 % kcal).
4
Recommended or lower (< 10 % kcal) and high (> 10 % kcal).
5
Recommended or lower (< 15 % kcal) and high (> 15 % kcal).
6
Recommended or lower (< 10 % kcal) and high (> 10 % kcal).
2
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Events/ total
176/501
100/279
105/300
170/477
202/569
12/40
205/589
7/15

HR (95% CI)2
Reference
1.12 (0.86, 1.45)
Reference
1.12 (0.86, 1.45)
Reference
0.94 (0.52, 1.71)
Reference
1.33 (0.57, 3.09)

p value
0.41
0.40
0.84
0.50

Table 3: Overall survival among dietary fat intake categories in early-stage and advanced-stage NSCLC patients by smoking status
and body mass index
Early-stage
Dietary fat intake
Never smokers

1

Events/total

Saturated fat3
4

Monounsaturated fat

Recommended or lower

24/55

Reference

High

23/49

1.62 (0.81, 3.25)

Recommended or lower

38/86

--

High
Ever smokers

3

Saturated fat

96/123

1.07 (0.80, 1.44)

--

176/227

Reference

0/3

10/14

219/428

0.027

Monounsaturated fat

Recommended or lower

204/483

1.31 (1.03, 1.67)
Reference

High

14/37

1.03 (0.59, 1.82)

0.91

Saturated fat3

Recommended or lower

61/131

Reference

High

97/176

1.23 (0.87, 1.74)

Recommended or lower

95/216

Reference

High
Saturated fat

4

Monounsaturated fat
3

Saturated fat

4

Monounsaturated fat

6/11

2.30 (0.94, 5.65)

Recommended or lower

51/103

Reference

High

89/178

1.02 (0.70, 1.48)

Recommended or lower

95/207

Reference

High
Obese

0.18

High

3

4/13

0.45 (0.16, 1.29)

0.24
0.069
0.91

21/66

Reference

56/123

0.012

Recommended or lower

52/146

2.06 (1.16, 3.63)
Reference

4/16

1.10 (0.36, 3.37)

0.87

High

Reference

607/731

0.91 (0.79, 1.05)

568/726

Reference

35/55

0.72 (0.50, 1.02)

210/248

Reference

302/351

0.98 (0.81, 1.18)

313/390

Reference

14/23

0.80 (0.47, 1.39)

138/171

Reference

235/295

0.92 (0.74, 1.15)

240/313

Reference

12/22

High

1.22 (0.63, 2.37)

320/387

0.14

Recommended or lower

1

HR (95% CI)2
Reference

Reference

Monounsaturated fat

Events/total
126/155

109/245

4

Overweight

p
value

Recommended or lower
4

Normal weight

HR (95% CI)2

Advanced-stage

59

0.64
0.55
0.19
0.064
0.82
0.43
0.48
0.039

98/123

0.53 (0.29, 0.97)
Reference

166/208

0.92 (0.70, 1.20)

0.53

191/250

Reference

19/24

0.97 (0.58, 1.62)

Fat intake was energy-adjusted by using the nutrient density method.
Multivariable model adjusted for age, gender, BMI, smoking status, stage, grade, pathology, and treatment where appropriate.
3
Recommended or lower (< 10 % kcal) and high (> 10 % kcal).
4
Recommended or lower (< 15 % kcal) and high (> 15 % kcal).
2

p
value

0.91

Table 4: Risk of overall survival by total and specific types of dietary fat intake stratified by stage and treatment type
Early-Stage
Surgery only
HR (95% CI)2

Early-Stage
Surgery and chemotherapy
Dead HR (95% CI)2
p value

Advanced-Stage
Primary chemotherapy
Dead HR (95% CI)2
p value

Dietary fat intake1
Dead
p value
3
Total fat
Recommended or lower 131
Reference
123
Reference
434
Reference
High
65
0.81 (0.59, 1.11) 0.20
58
1.11 (0.78, 1.56) 0.57
221
0.90 (0.76, 1.07)
4
Saturated fat
Recommended or lower
66
Reference
67
Reference
261
Reference
High
129
1.25 (0.91, 1.72) 0.17
113
1.32 (0.95, 1.84) 0.10
397
0.84 (0.71, 0.99)
5
Monounsaturated fat
Recommended or lower 119
Reference
123
Reference
454
Reference
High
11
1.23 (0.65, 2.34) 0.52
3
0.51 (0.16, 1.68) 0.27
27
0.64 (0.43, 0.96)
Polyunsaturated fat6
Recommended or lower 128
Reference
125
Reference
477
Reference
High
2
0.86 (0.20, 3.66) 0.83
2
0.55 (0.12, 2.40) 0.42
8
0.63 (0.31, 1.28)
1
Fat intake was energy-adjusted by using the nutrient density method.
2
Multivariable model adjusted for age, gender, BMI, smoking status, stage, grade, pathology and treatment where appropriate.
3
Recommended or lower (< 35 % kcal) and high (> 35 % kcal).
4
Recommended or lower (< 10 % kcal) and high (> 10 % kcal).
5
Recommended or lower (< 15 % kcal) and high (> 15 % kcal).
6
Recommended or lower (< 10 % kcal) and high (> 10 % kcal).
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0.24

0.036

0.030

0.20

Figure: Distribution of fat intake in the study population
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Supplemental
Supplemental Table 1: Characteristics of NSCLC patients by saturated fat intake
Saturated fat intake1, n (%)2
Low
Recommended
High
Characteristics
(n = 60)
(n = 810)
(n = 1,395)
Age at diagnosis, year
64.7 + 9.74
64.3 + 10.7
62.3 + 10.9
Sex
Men
24 (40.0)
400 (49.4)
738 (52.9)
Women
36 (60.0)
410 (50.6)
657 (47.1)
Education
High school or less
19 (31.7)
281 (34.7)
548 (39.4)
Some college
19 (31.7)
267 (33.0)
455 (32.7)
Complete college or greater 22 (36.7)
261 (32.3)
389 (27.9)
Smoking status Never
10 (16.7)
211 (26.0)
180 (12.9)
Former
35 (58.3)
382 (47.2)
622 (44.6)
Current
15 (25.0)
217 (26.8)
593 (42.5)
2
BMI, kg/m
< 25
29 (48.3)
364 (44.9)
547 (39.2)
25-30
19 (31.7)
265 (32.7)
498 (35.7)
> 30
12 (20.0)
181 (22.3)
350 (25.1)
Total energy, kcal/d
1772.9 + 704.3 1973.6 + 770.4 2046.8 + 713.4
Clinical stage
I and II
22 (37.3)
278 (35.5)
477 (35.8)
III and IV
37 (62.7)
505 (64.5)
854 (64.2)
Grade
Well differentiated
4 ( 6.7)
69 ( 8.5)
81 ( 5.8)
Moderately differentiated
11 (18.3)
184 (22.7)
310 (22.2)
Poorly differentiated
26 (43.3)
328 (40.5)
585 (41.9)
Undifferentiated
0
4 ( 0.5)
19 ( 1.4)
Unknown
19 (31.7)
225 (27.8)
400 (28.7)
Pathology
Adenocarcinoma
36 (60.0)
489 (60.4)
757 (54.3)
Squamous cell
15 (25.0)
176 (21.7)
344 (24.7)
Large cell
6 (10.0)
101 (12.5)
206 (14.8)
Others
3 ( 5.0)
44 ( 5.4)
88 ( 6.3)
Surgery
No
35 (58.3)
474 (58.5)
876 (62.8)
Yes
25 (41.7)
336 (41.5)
519 (37.2)
Radiation
No
47 (78.3)
636 (78.5)
1069 (76.6)
Yes
13 (21.7)
174 (21.5)
326 (23.4)
Chemotherapy
No
26 (43.3)
400 (49.4)
744 (53.3)
Yes
34 (56.7)
410 (50.6)
651 (46.7)
Chemoradiation No
54 (90.0)
691 (85.3)
1155 (82.8)
Yes
6 (10.0)
119 (14.7)
240 (17.2)
1
Fat intake was energy-adjusted by using the nutrient density method. Low (< 6 % kcal),
recommended (6-10 % kcal) and high (> 10 % kcal).
2
Numbers may not add up to the total because of missing data.
3
Derived by using chi-square test for categorical variables and ANOVA for continuous variables.
4
Mean + SD (all such values).
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p value3
< 0.0001
0.06

0.10

< 0.0001

0.08
< 0.0001
0.96

0.19

0.19
0.13
0.58
0.08
0.13

Supplemental Table 2: Characteristics of NSCLC patients by monounsaturated fat intake
Monounsaturated fat intake1, n (%)2
Low
Recommended
High
Characteristics
(n = 475)
(n = 1,095)
(n = 114)
Age at diagnosis, year
64.2 + 11.14
62.9 + 11.4
62.0 + 10.4
Sex
Men
205 (43.2)
583 (53.2)
62 (54.4)
Women
270 (56.8)
512 (46.8)
52 (45.6)
Education
High school or less
162 (34.1)
392 (35.9)
44 (38.9)
Some college
158 (33.3)
383 (35.1)
37 (32.7)
Complete college or greater 155 (32.6)
317 (29.0)
32 (28.3)
Smoking status
Never
119 (25.1)
206 (18.8)
18 (15.8)
Former
229 (48.2)
467 (42.6)
53 (46.5)
Current
127 (26.7)
422 (38.5)
43 (37.7)
BMI, kg/m2
< 25
214 (45.1)
410 (37.4)
35 (30.7)
25-30
155 (32.6)
380 (34.7)
36 (31.6)
> 30
106 (22.3)
305 (27.9)
43 (37.7)
Total energy, kcal/d
1932.1 + 777.4 2080.9 + 765.3
1938.3 + 549.6
Clinical stage
I and II
162 (35.2)
407 (38.3)
40 (36.7)
III and IV
298 (64.8)
655 (61.7)
69 (63.3)
Grade
Well differentiated
38 ( 8.0)
68 ( 6.2)
6 ( 5.3)
Moderately differentiated
101 (21.3)
276 (25.2)
26 (22.8)
Poorly differentiated
184 (38.7)
409 (37.4)
52 (45.6)
Undifferentiated
1 ( 0.2)
11 ( 1.0)
1 ( 0.9)
Unknown
151 (31.8)
331 (30.2)
29 (25.4)
Pathology
Adenocarcinoma
309 (65.1)
633 (57.8)
49 (43.0)
Squamous cell
90 (18.9)
266 (24.3)
41 (36.0)
Large cell
54 (11.4)
150 (13.7)
21 (18.4)
Others
22 ( 4.6)
46 ( 4.2)
3 ( 2.6)
Surgery
No
290 (61.1)
646 (59.0)
64 (56.1)
Yes
185 (38.9)
449 (41.0)
50 (43.9)
Radiation
No
376 (79.2)
856 (78.2)
89 (78.1)
Yes
99 (20.8)
239 (21.8)
25 (21.9)
Chemotherapy
No
228 (48.0)
511 (46.7)
54 (47.4)
Yes
247 (52.0)
584 (53.3)
60 (52.6)
Chemoradiation
No
401 (84.4)
899 (82.1)
98 (86.0)
Yes
74 (15.6)
196 (17.9)
16 (14.0)
1
Fat intake was energy-adjusted by using the nutrient density method. Low (< 10 % kcal),
recommended (10-15 % kcal) and high (> 15 % kcal).
2
Numbers may not add up to the total because of missing data.
3
Derived by using chi-square test for categorical variables and ANOVA for continuous variables.
4
Mean + SD (all such values).
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p value3
0.02
0.0008

0.62

0.0001

0.002
0.0001
0.51

0.27

0.0004
0.57
0.90
0.89
0.36

Supplemental Table 3: Characteristics of NSCLC patients by polyunsaturated fat intake

Characteristics

Polyunsaturated fat intake1, n (%)2
Low
Recommended High
(n = 205)
(n = 1,441)
(n = 37)
4

Age at diagnosis, year
63.1 + 12.1
63.2 + 11.2
62.5 + 12.1
Sex
Men
111 (54.1)
725 (50.3)
12 (32.4)
Women
94 (45.9)
716 (49.7)
25 (67.6)
Education
High school or less
68 (33.2)
515 (35.8)
14 (37.8)
Some college
69 (33.7)
495 (34.4)
13 (35.1)
Complete college or greater
68 (33.2)
427 (29.7)
10 (27.0)
Smoking status
Never
33 (16.1)
302 (21.0)
6 (16.2)
Former
95 (46.3)
633 (43.9)
20 (54.1)
Current
77 (37.6)
506 (35.1)
11 (29.7)
BMI, kg/m2
< 25
94 (45.9)
549 (38.1)
13 (35.1)
25-30
62 (30.2)
501 (34.8)
10 (27.0)
> 30
49 (23.9)
391 (27.1)
14 (37.8)
Total energy, kcal/d
2007.0 + 796.1 2041.2 + 759.1
1708.8 + 492.8
Clinical stage
I and II
73 (36.0)
516 (37.1)
15 (42.9)
III and IV
130 (64.0)
876 (62.9)
20 (57.1)
Grade
Well differentiated
13 ( 6.3)
98 ( 6.8)
2 ( 5.4)
Moderately differentiated
40 (19.5)
355 (24.6)
8 (21.6)
Poorly differentiated
95 (46.3)
538 (37.3)
13 (35.1)
Undifferentiated
0
12 ( 0.8)
1 ( 2.7)
Unknown
57 (27.8)
438 (30.4)
13 (35.1)
Pathology
Adenocarcinoma
137 (66.8)
836 (58.0)
18 (48.6)
Squamous cell
40 (19.5)
343 (23.8)
12 (32.4)
Large cell
21 (10.2)
198 (13.7)
5 (13.5)
Others
7 ( 3.4)
64 ( 4.4)
2 ( 5.4)
Surgery
No
118 (57.6)
863 (59.9)
23 (62.2)
Yes
87 (42.4)
578 (40.1)
14 (37.8)
Radiation
No
170 (82.9)
1123 (77.9)
30 (81.1)
Yes
35 (17.1)
318 (22.1)
7 (18.9)
Chemotherapy
No
94 (45.9)
681 (47.3)
14 (37.8)
Yes
111 (54.1)
760 (52.7)
23 (62.2)
Chemoradiation
No
167 (81.5)
1198 (83.1)
32 (86.5)
Yes
38 (18.5)
243 (16.9)
5 (13.5)
1
Fat intake was energy-adjusted by using the nutrient density method. Low (< 5 % kcal),
recommended (5-10 % kcal) and high (> 10 % kcal).
2
Numbers may not add up to the total because of missing data.
3
Derived by using chi-square test for categorical variables and ANOVA for continuous variables.
4
Mean + SD (all such values).
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p value3
0.88
0.05

0.86

0.40

0.14
0.77
0.74

0.25

0.24
0.78
0.25
0.50
0.71
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Abstract
Alterations in fatty acid metabolism may affect cancer development and progression. In this
two-stage study, we assessed associations between 691 single nucleotide polymorphisms
(SNPs) in 94 genes involved in fatty acid metabolism and overall survival and recurrence
among non-Hispanic whites with non-small cell lung cancer (NSCLC), and further evaluated
whether the associations varied by dietary fat intake. Among 1,593 NSCLC patients in the
discovery set, we identified candidate SNPs associated with overall survival or recurrence.
Those SNPs were further validated in the replication set of 746 NSCLC patients. We identified
four SNPs associated with overall survival and one SNP associated with recurrence that were
consistently significant in both datasets. Functional assessment identified three variants
ACSL1:rs4862417, CYP2C8:rs1934953, and FADS2:rs174611 to be putatively functional.
Early-stage patients with a G variant of rs174611 were associated with 28% and 47% increased
risk of death in the discovery (95% confidence interval: 1.03, 1.59) and replication sets (95%
confidence interval: 1.03, 2.08), respectively. Monounsaturated fat intake was found to interact
with the rs174611 genotype in relation to overall survival (multiplicative Pinteraction = 0.03).
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Genetic variants and dietary fat intake may have multiplicative effect on overall survival in
NSCLC.

Keywords: fatty acids, single nucleotide polymorphism, genetics, non-small cell lung cancer,
survival, recurrence, monounsaturated fat
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Introduction
Lung cancer continues to be the most frequently diagnosed cancer and the leading cause of
cancer death in the United States (1). Although progress has been made in the treatment for
lung cancer, the overall 5-year survival rate is only 18% (2). Non-small cell lung cancer
(NSCLC) is the major histological subtype of lung cancer, accounting for 80-85% of all lung
cancer cases (1). Prognostic factors for survival of NSCLC include age at diagnosis, gender,
performance status, and tumor stage (3). In addition, a variety of genes and signaling pathways
have been shown to be associated with survival and tumor progression in NSCLC patients (4,
5).
The importance of fatty acid metabolism in cancer has been increasingly recognized (6, 7).
Fatty acids are one of the main macronutrients, which can be externally derived through daily
diet intake and internally derived through de novo fatty acids synthesis. Tumor cells often have
fatty acid metabolic abnormalities (7), and rely mostly on de novo fatty acid synthesis instead
of uptake of exogenous fatty acid (8). Alterations in fatty acid metabolism in tumor cells favor
excessive fatty acids for synthesis of membranes and signaling molecules to meet the demands
of cancer cell proliferation (6). The rate of fatty acids synthesis is controlled by a series of
enzymatic regulation, including ATP citrate lyase (ACLY), acetyl-CoA carboxylase-α
(ACACA), and fatty acid synthase (FASN) (9). These enzymes are highly up-regulated in lung
cancer cells (10, 11), as well as prostate, breast, colorectal, stomach, and endometrial cancer
cells (12-15). Moreover, overexpression of FASN shows an aggressive clinical behavior in
patients with lung cancer (16).
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Previous research has documented that single nucleotide polymorphisms (SNPs) in fatty
acid synthesis genes are associated with prognosis among NSCLC patients who received
surgery (17), but the scope was limited to a small subset of variants in a few genes related to
fatty acid synthesis. The broader impact of genetic variants in genes involved in the fatty acid
metabolism in clinical outcomes among NSCLC patients remain unclear. Therefore, we aimed
to systematically investigate the associations between SNPs in fatty acid metabolism genes
and overall survival and recurrence in NSCLC by using two-stage design, and further examine
whether the associations were modified by dietary fat intake.

Methods
Study population and recruitment
Study participants were accrued from an ongoing epidemiology study of lung cancer at The
University of Texas MD Anderson Cancer Center (MDACC) between 1995 and 2008. The
study was approved by Institutional Review Board of MDACC and all study participants
provided written informed consent. There were no recruitment restrictions on age, sex,
ethnicity, histology, and stage. All participants were newly-diagnosed within 1 year of
recruitment, histologically confirmed, and had not previously received cancer treatment prior
to study recruitment. Each study participant underwent a 45-minute in-person interview by
trained staff, and at the end of interview a 40 mL peripheral blood sample was drawn for
molecular analysis. To be eligible for this current analysis, study participants must have had
existing genotyping data available from previous genome-wide association studies (GWAS)
and the OncoArray project (18-20). The previous studies only included non-Hispanic white
68

NSCLC patients for a total of 1,593 in the discovery (GWAS) and 746 in the replication
(OncoArray).

Data collection
A structured questionnaire was used to collect epidemiological data from all study
participants, including demographic characteristics, smoking status, and weight at diagnosis.
Trained staff abstracted clinical and follow-up information from medical records. Early-stage
NSCLC was categorized as clinical stages I and II, and those with stages III and IV were
classified as advanced-stage NSCLC.
Nutrient data were collected in a subset of study participants using a modified version of
the National Cancer Institute’s Health Habits and History Questionnaire that was previously
validated (21). The details about our dietary assessment have been previously described (22,
23). Our food frequency questionnaire (FFQ) asked study participants about the frequency and
portion sizes of 165 food and beverage items consumed during the year prior to NSCLC
diagnosis. Nutrient calculations were done using the US Department of Agriculture National
Nutrient Database for Standard Reference and Food and Nutrient Database for Dietary Studies
(24, 25). Energy-adjusted dietary intakes were obtained by nutrient density method on intakes
of total, saturated, monounsaturated, and polyunsaturated fat.

SNP selection
We selected fatty acid metabolism genes that were included in both Reactome
(reactome.org/) and Kyoto Encyclopedia of Genes and Genomes [(KEGG) genome.jp/kegg/]
databases. These fatty acid metabolism genes included those involved in fatty acid
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biosynthesis, elongation, and degradation; arachidonic acid metabolism; alpha-linolenic and
linoleic acid metabolism; glycerolipid metabolism; glycerophospholipid metabolism; and
sphingolipid metabolism. There were 97 genes including in both bioinformatics resources.
After excluding genes that were not found in The University of California Santa Cruz (UCSC)
Genome Browser [genome.ucsc.edu, (n=3)], 94 genes were reported to be associated with fatty
acid metabolism. A total of 691 SNPs mapped 10 kb upstream or 10 kb downstream of 94
genes were included in the discovery set. rAggr (raggr.usc.edu/) was used to identify proxy
SNPs (with r2 > 80%) as substitutes for those SNPs that were not directly genotyped in the
replication set.

Statistical analysis
Person-time was calculated individually for overall survival and recurrence. Overall
survival was defined as the period from the date of diagnosis to the date of death from any
cause, or the last follow-up, whichever came first. Time to recurrence was defined as the date
of diagnosis to first recurrence, or the date of the last follow-up among early-stage patients,
depending on which date came first. Recurrence was defined as tumor recurring locally,
regionally, and at distant metastasis sites after curative resection. Analyses of the associations
between SNPs in fatty acid metabolism genes and clinical outcomes among NSCLC patients
were conducted by using multivariable Cox proportional hazards regression models with
adjustment for age, sex, smoking status, clinical stage, performance status, and treatment
regimen in the discovery and replication sets. Hazard ratios (HRs) and 95% confidence
intervals (CIs) were estimated from the Cox regression model. All genetic models of
inheritance including the dominant, recessive, and additive models were taken into
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consideration in the assessment. The genetic model with the smallest P value was considered
as the best-fitting model. We used Q value to control the false discovery rate since many SNPs
were tested for the associations with clinical outcomes. All the significant SNPs had Q value
< 0.20 in the discovery set.
Expression quantitative trait loci (eQTL) analysis was utilized to conduct functional
characterization of the significant SNPs that had consistent associations with overall survival
or recurrence in both discovery and replication sets using genomic data from the GenotypeTissue Expression (GTEx) project (26). We also considered functional annotations of the proxy
variants in high linkage disequilibrium (LD) to the significant SNPs using HaploReg v4.1 (27).
The putatively functional SNPs were further examined the potential impact of dietary fat
intake on the associations between the significant SNPs and overall survival and recurrence in
a subset of study participants. A total of 1,993 participants were included after excluding four
participants with outlying energy intake with values that laid outside the intervals delimited by
the 25th percentile minus 1.5 times the interquartile range (IQR) and the 75th percentile plus
1.5 times the IQR, and implausible energy intake with values for energy intake below 500
kcal/d or above 5,000 kcal/d. Total and subtypes of dietary fat intake were categorized by their
medians. Dietary intakes of total and specific types of fat were energy-adjusted prior to further
analysis (28). The associations between dietary fat intake and overall survival and recurrence
were examined via the multivariable Cox regression model adjusting for age, sex, body mass
index (BMI) at diagnosis, smoking status, clinical stage, performance status, and treatment
regimen. We tested for additive and multiplicative interaction between the significant SNPs
and dietary fat intake in the multivariable Cox regression model. All analyses were performed
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with Stata (College Station, TX), and two-sided P value < 0.05 was considered statistically
significant.

Results
The characteristics of the 1,593 NSCLC patients in the discovery set and 746 NSCLC
patients in the replication set are shown in Table 1. The mean age at diagnosis in the discovery
set was 62 years and 65 years in the replication set. The majority of study participants were
males, former or current smokers, and reported performance status score of one indicating
limitations in physically strenuous activity.
For overall survival, there were 70 SNPs that were significantly associated with overall
survival in the discovery set, of which one SNP was validated in the replication set. This variant
CYP2C19:rs7916649 was associated with a 15% increased risk of death in the discovery set
(95% CI: 1.01, 1.32) and 46% increase in the replication set (95% CI: 1.02, 2.09) under the
dominant model (Table 2). A total of 68 SNPs were associated with recurrence in the discovery
set, and only one variant in PLA2G4A was consistently associated with increased recurrence
of NSCLC. Patients with G allele (AG or GG genotypes) of rs10911933 had 109% and 67%
increased risk of death in the discovery (95% CI: 1.48, 2.95) and replication sets (95% CI:
1.00, 2.79), respectively.
When we assessed the effect on survival by stage grouping, there were 57 SNPs and 87
SNPs significant in patients with early-stage and advanced-stage NSCLC in the discovery set,
respectively. Among these SNPs, three SNPs remained consistent and significant in association
with overall survival among early-stage patients and were predicted to be putatively functional,
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but no SNP was replicated among advanced-stage patients. Early-stage NSCLC patients with
variant ACSL1:rs4862417 conferred a 28% improvement in overall survival in the discovery
set (95% CI: 0.54, 0.96), and 39% improvement in the replication set (95% CI: 0.37, 0.99)
under the dominant model. The proxy SNP, rs2292899 in high LD with ACSL1:rs4862417 was
predicted to be a weak transcriptional regulator based on its location in 3’ untranslated region
(3’UTR) and enhancer-like region. Those with two recessive alleles of rs1934953 in CYP2C8
had 42% and 80% decreased risk of survival in the discovery (95% CI: 0.36, 0.95) and
replication sets (95% CI: 0.06, 0.66), respectively. The predicted location of genotyped variant,
CYP2C8:rs1934953, was in a transcription factor binding site for IRF2 that modulates cellular
responses and involves in tumorigenesis. This variant was also identified as a direct eQTL
regulating expression of CYP2C8 in thyroid, testis, stomach and muscle tissues. In the same
subgroup, the variant FADS2:rs174611 was associated with a 28% increased risk of death in
the discovery set (95% CI: 1.03, 1.59), and 47% increase in the replication set (95% CI: 1.03,
2.08) under the additive model. The variant FADS2:rs174611 was predicted to be located in
the enhancer-like region as well as the transcription factor binding site for ELF1, and a direct
eQTL regulating expression of FADS2 was found in lung tissues.
In a subset of study participants with nutrient data collected (N = 1,993), the multivariableadjusted results for the associations between total and specific types of fat intake and clinical
outcomes in NSCLC are shown in Table 3. High intake of saturated fat was associated with a
13% increased risk of death (95% CI: 1.00, 1.26), but associations between other types of
dietary fat and overall survival were not significant among NSCLC patients. There was a
marginally significant survival reduction of high intake of monounsaturated fat among early73

stage patients. Moreover, those with high intake of monounsaturated fat were associated with
a 63% increased risk of recurrence (95% CI: 1.22, 2.19), and an unfavorable effect on
recurrence was borderline significant with high intake of total fat.
To elucidate potential interactions between the putatively functional SNPs and dietary fat
intake effects on overall survival among early-stage NSCLC patients, we further stratified the
analysis (Table 4). Stratification by low and high intake of monounsaturated fat showed
consistent associations for overall survival by ACSL1 and CYP2C8 SNPs, although neither of
were significant. In contrast, low intake of monounsaturated fat was associated with poor
survival for early-stage patients with the variant (AG or GG) rs174611 genotype (HR: 2.29,
95% CI: 1.32, 3.96), whereas null association was observed in the high intake of
monounsaturated fat subgroup. The variant rs174611 showed evidence of no additive
interaction, but a multiplicative interaction with monounsaturated fat intake (P for interaction
= 0.035).

Discussion
In this present study, we found that genetic variants CYP2C19:rs7916649,
ACSL1:rs4862417, CYP2C8:rs1934953 and FADS2:rs174611 were associated with overall
survival among NSCLC patients, whereas the associations with SNPs in ACSL1, CYP2C8, and
FADS2 were only observed in early-stage patients. The variant PLA2G4A:rs10911933 was also
associated with recurrence. These associations were consistent and significant in both
discovery and replication sets. Moreover, the association between variant in FADS2 and risk
of death was modified by monounsaturated fat intake, and was seemingly confined to early74

stage NSCLC patients with G allele (AG and GG genotypes) of rs174611 who had low intake
of monounsaturated fat.
Previous studies have investigated the role of genetic variation in genes encoding fatty acid
metabolism enzymes and cancer outcomes. A study examined eight SNPs in ACLY, ACACA,
and FASN as predictors of overall survival and recurrence among NSCLC patients treated with
surgery in a Chinese population (17). Although they found no association between variants in
ACACA and survival or recurrence, ACLY:rs9912300 was shown to be associated with overall
survival, and two SNPs in FASN, rs4246444 and rs4485435, were associated with recurrence.
Another group used data from another Chinese population, and identified that two SNPs in
ACACA were associated with survival among hepatocellular carcinoma patients who
underwent surgery, while also confirming the possible role of FASN:rs4485435 in survival
(29). Finally, a study from European American men treated with radical prostatectomy showed
a weak association between FASN:rs4246444 and disease recurrence (30). Unlike previous
studies, our study took a more systematic approach by including 691 SNPs in 94 genes
involved in fatty acid metabolism, but found that genetic variation in ACLY, ACACA, and
FASN was not associated with overall survival or recurrence for NSCLC patients. Moreover,
no such association was observed when the analysis was stratified by patients with early-stage
and advanced-stage NSCLC. However, we identified five novel SNPs that were associated
with overall survival and recurrence in NSCLC patients, and three of them in ACSL1, CYP2C8,
and FADS2 were predicted to be functional.
FADS2 located on 11q12.2 encodes a desaturase enzyme that controls the biosynthesis of
unsaturated fatty acids from polyunsaturated fatty acids. FADS2 has been found to be highly
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expressed in lung tumor tissue (31). FADS2:rs174611 was predicted to be located in a
transcription factor binding site for ELF1, a member of ETS transcription factor family that
has been shown to regulate cell proliferation in epithelial cells (32). ETS is highly expressed
in lung cancer patients with advanced clinical stage and is associated with poor survival (33).
The expression of ETS in lung cancer tissue is positively associated with VEGF (34). Previous
studies have suggested that ELF1 serves as an intermediate in the oncogenesis process through
VEGF (35, 36). VEGF is a key mediator of angiogenesis by binding to specific VEGF
receptors, leading to subsequent signal transduction in facilitating proliferation and migration
in common cancers, including NSCLC (37). The VEGF signaling activates ETS1 that regulates
the expression of TEK (38), and TEK has also been reported to be regulated by ELF1 (39).
Moreover, eQTL analysis for FADS2:rs174611 in lung tissue suggested that the risk allele of
rs174611 was associated with a significantly increased FADS2 expression.
Previous studies have indicated that genetic variations in FADS2 influenced fatty acid
composition in circulation, cells, and tissues (40). In addition, a significant decrease in
triglyceride and low density lipoprotein cholesterol levels following monounsaturated fatty
acids-rich diets has been observed (41). Dietary recommendations for fatty acid intake have
been suggested to replace saturated fat with monounsaturated fat to prevent heart diseases (42).
It has been recognized that monounsaturated fat intake has anti-inflammatory action that may
contribute to suppress tumor cell proliferation and progression (43). The association between
monounsaturated fat intake and prognosis of common cancers has been examined, not
including lung cancer, but studies yield inconsistent results (44-46). Our study showed no
evidence for associations between high intake of monounsaturated fat and overall survival and
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recurrence in NSCLC patients. We observed that high intake of monounsaturated fat was
associated with worse survival among early-stage NSCLC although the association was
borderline significant. Nevertheless, the unfavorable effect on survival disappeared among
early-stage patients with high intake of monounsaturated fat who carry at least one copy of G
allele of rs174611 compared to those with no risk allele. Given that the variant
FADS2:rs174611 affects tumorigenesis through activation of VEGF, patients with high intake
of monounsaturated fat exhibit alleviated inflammation in response to proinflammatory stimuli
of VEGF among those who carry the variant. In contrast, those with low intake of
monounsaturated fat who carry the variant may not have the ability to impede the inflammation
via VEGF resulting in a poorer survival. Our finding showed that the association between
rs174611 genotype and overall survival in early-stage NSCLC was modified by
monounsaturated fat intake. Further research is needed to explore the biological mechanism of
how monounsaturated fat and the variant rs174611 interact to cause differences in survival
among NSCLC patients.
ACSL1 is located on chromosome 4q35.1 encoding for a long-chain fatty acid enzyme that
converts long-chain fatty acid into fatty acyl-CoA ester and plays a vital role in fatty acid
synthesis and degradation. ACSL1 has been shown to be downregulated in lung cancer tissue,
and lower expression of ACSL1 is associated with better survival (47). A variant in high LD
with ACSL1:rs4862417, rs2292899, was predicted to have functional effects on transcriptional
regulation through methylation, although the predicted effect was weak.
CYP2C8 located on chromosome 10q24 is a multifunctional enzyme involved in drug
metabolism and lipid synthesis, particularly the conversion of long-chain polyunsaturated fatty
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acids to epoxyeicosatrienoic acids or monounsaturated fatty acids. CYP2C8:rs1934953 was
predicted to be located in a transcription factor binding site for IRF2 that plays an antioncogenic role. IRF2 has been shown to promote cell apoptosis, and inhibit cell proliferation
and migration in lung cancer (48). A direct eQTL regulating expression of CYP2C8 was
observed in thyroid, testis, stomach and muscle tissues. Additional eQTL data from lung tissue
is needed to unravel the underlying relationship.
The present study had some strengths and limitations. To the best of our knowledge, this is
the first study to systematically investigate the associations between genetic variation in genes
involved in fatty acid metabolism and overall survival and recurrence in NSCLC. It is also the
first study to evaluate the potential impact of dietary fat intake on theses associations.
Additionally, the significant SNPs associated with overall survival and recurrence were
identified and validated by using two datasets to minimize false positive associations.
However, a potential weakness is recall bias because information about dietary fat intake over
the past year prior to diagnosis was based on self-report. However, it is unlikely that the
measurement error was the differential of clinical outcomes. In addition, this study includes
only non-Hispanic whites, and thus our study results may not be directly generalizable to other
ethnic populations. Lastly, we should be cautious about the generalization from the findings of
our study, since external validation is lacking.
In summary, our study provides support for the hypothesis that germline genetic variants in
fatty acid metabolism genes play a critical role in overall survival among patients with earlystage NSCLC. Specifically, early-stage patients with variants ACSL1:rs4862417 and
CYP2C8:rs1934953 may improve their survival. By contrast, those with variant
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FADS2:rs174611 may have poor survival, and this risk may be further modified by
monounsaturated fat intake. This study suggests that the effect of genetic variants in fatty acid
metabolism genes on overall survival in NSCLC is likely to be complex, and further
investigation should be conducted to provide insights into the mechanisms underlying the
association.
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Table 1: Characteristics of NSCLC patients in discovery and replication sets
Discovery
(n = 1593)
Characteristics
No.
%
1
Age at diagnosis
62.03 (11.06)
Sex
Men
820
51.5
Women
773
48.5
Smoking status
Never
278
17.5
Former
699
43.9
Current
616
38.7
Clinical stage
I and II
492
31.8
III and IV
1057
68.2
Performance status 0
334
29.8
1
638
56.9
2-4
150
13.4
Surgery
Yes
593
37.2
No
1000
62.8
Radiation
Yes
379
23.8
No
1214
76.2
Chemotherapy
Yes
803
50.4
No
790
49.6
Chemoradiation
Yes
292
18.3
No
1301
81.7
Abbreviations: NSCLC, non-small cell lung cancer.
1
Values are expressed as mean (standard deviation).
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Replication
(n = 746)
No.
%
65.20 (9.78)
381
51.1
365
48.9
38
9.3
226
55.5
143
35.1
405
54.3
341
45.7
157
28.6
328
59.9
63
11.5
335
44.9
411
55.1
189
25.3
557
74.7
380
50.9
366
49.1
120
16.1
626
83.9

Table 2: Overall survival and recurrence by fatty acid metabolism gene variants in NSCLC patients
Discovery
SNP

Gene

Replication

MOD

Genotype

Events

Nonevents

HR1
95% CI

Dom

GG\GA\AA

323\577\223

171\222\75

1.15
1.01, 1.32

P
Value

Events

Nonevents

HR1
95% CI

P
Value

0.036

95\166\64

149\189\83

1.46
1.02, 2.09

0.039

0.027

78\43\4

154\108\18

0.029

58\60\7

120\111\47

0.026

51\57\17

144\113\23

2.5x10-5

85\47\5

184\79\4

Overall survival
rs7916649

CYP2C19

Overall survival among early-stage NSCLC
rs4862417

ACSL1

Dom

AA\AG\GG

119\74\12

147\123\16

rs1934953

CYP2C8

Rec

AA\AG\GG

83\103\20

111\135\40

rs1746112

FADS2

Add

AA\AG\GG

87\99\20

145\117\24

PLA2G4A

Dom

AA\AG\GG

100\67\11

244\69\1

0.72
0.54, 0.96
0.58
0.36, 0.95
1.28
1.03, 1.59

0.61
0.37, 0.99
0.20
0.06, 0.66
1.47
1.03, 2.08

0.048
0.008
0.031

Recurrence
rs109119332

2.09
1.48, 2.95

1.67
1.00, 2.79

Abbreviations: SNP, single nucleotide polymorphisms; MOD, model; MAF, minor allele frequency; Dom, dominant; Add,
additive; HR, hazard ratio; CI, confidence interval; NSCLC, non-small cell lung cancer.
1
Multivariable models were adjusted for age, gender, smoking status, clinical stage, performance status, and treatment regimen.
2
Proxy SNP with high linkage disequilibrium (R2 > 0.8) was used in replication set.
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0.049

Table 3: Overall survival and recurrence by total and specific types of dietary fat intake among
NSCLC patients
Dietary fat intake1
Overall survival
Total fat2
3

Saturated fat

4

Monounsaturated fat
Polyunsaturated fat

5

Early-stage
Total fat2
3

Saturated fat

4

Monounsaturated fat
Polyunsaturated fat

5

Events/
total

Multivariable-adjusted6
HR
95% CI
P Value

Low
High
Low
High
Low
High
Low
High

615/980
645/979
605/980
656/979
424/722
435/722
434/723
429/723

1.00
1.03
1.00
1.13
1.00
1.05
1.00
1.04

Referent
0.92, 1.16
Referent
1.00, 1.26
Referent
0.91, 1.20
Referent
0.91, 1.19

Low
High
Low
High
Low
High
Low
High

134/374
139/348
126/364
146/356
95/294
104/278
95/289
104/278

1.00
1.22
1.00
1.19
1.00
1.32
1.00
1.16

Referent
0.95, 1.56
Referent
0.93, 1.53
Referent
0.99, 1.76
Referent
0.87, 1.55

Recurrence
Total fat2

0.58
0.042
0.51
0.59

0.11
0.18
0.060
0.31

Low 129/374
1.00
Referent
High 132/348
1.28
0.97, 1.66
0.064
3
Saturated fat
Low 122/364
1.00
Referent
High 138/356
1.24
0.96, 1.61
0.099
4
Monounsaturated fat
Low 91/294
1.00
Referent
High 115/278
1.63
1.22, 2.19
0.001
5
Polyunsaturated fat
Low 100/289
1.00
Referent
High 104/278
1.16
0.87, 1.55
0.32
Abbreviations: HR, hazard ratio; CI, confidence interval; NSCLC, non-small cell lung
cancer.
1
Fat intake was energy-adjusted by using the nutrient density method.
2
Low (< 32.9 % kcal) and high (> 32.9 % kcal).
3
Low (< 10.8 % kcal) and high (> 10.8 % kcal).
4
Low (< 11.3 % kcal) and high (> 11.3 % kcal).
5
Low (< 6.6 % kcal) and high (> 6.6 % kcal).
6
Multivariable model adjusted for age, gender, BMI, smoking status, clinical stage,
performance status, and treatment regimen.
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Tables 4: Associations between genotype of the risk-associated SNPs and overall survival
among early-stage NSCLC patients stratified by monounsaturated fat intake

SNP

Genotype

rs4862417
(ACSL1)
rs1934953
(CYP2C8)
rs174611
(FADS2)

AA
AG or GG
AA or AG
GG
AA
AG or GG

Monounsaturated fat intake
Low
(n = 294)
Events HR1 95% CI
/Total
60/161 1.00 Referent
34/132 0.66 0.38, 1.15
87/252 1.00 Referent
8/41
0.52 0.21, 1.26
33/142 1.00 Referent
62/152 2.29 1.32, 3.96

High
(n = 277)
Events
/Total
57/152
46/125
96/244
7/33
54/142
49/135

P for
interaction2
HR1

95% CI

1.00
0.70
1.00
0.75
1.00
1.00

Referent
0.39, 1.25
Referent
0.28, 2.02
Referent
0.57, 1.75

0.60
0.65
0.035

Abbreviations: SNP, single nucleotide polymorphisms; HR, hazard ratio; CI, confidence
interval; NSCLC, non-small cell lung cancer.
1
Multivariable model adjusted for age, gender, BMI, smoking status, clinical stage,
performance status, and treatment regimen.
2
Multiplicative interaction from cross-product term in Cox regression model between
monounsaturated fat (high/low) and each SNP.
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CHAPTER V: CONCLUSION

Summary of Results
This dissertation provides a comprehensive investigation into the role of dietary fatty acids
in clinical outcomes among patients with non-small cell lung cancer (NSCLC). Specifically,
this dissertation starts with examining the associations of dietary fat intake with overall
survival and recurrence, and then identifies genetic variants in fatty acid metabolism genes that
are associated with NSCLC survival in non-Hispanic whites, and how this association is
influenced by fat intake.
In Chapter III, a total of 2,262 NSCLC patients were asked to recall the frequency and
portion sizes of fatty acids that they had eaten one year before lung cancer diagnosis using a
modified food frequency questionnaire at study enrollment. They were followed from the time
of diagnosis to death from any cause and recurrence, or the last follow-up during a median
follow-up of 23 months. This study showed that neither high intake of total fat, nor any subtype
of fat including saturated, monounsaturated and polyunsaturated fat, was associated with
overall survival or recurrence for NSCLC. The association between dietary fat intake and
overall survival was examined individually for early-stage patients and advanced-stage
patients, and the results were different. In particular, high intake of saturated fat was associated
with increased risk of death among early-stage NSCLC patients, whereas a protective effect
was observed in advanced-stage patients who received primary chemotherapy. A protective
effect of high intake of monounsaturated fat on overall survival was also found in these
advanced-stage patients.
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Previous studies demonstrated that red meat consumption was positively associated with
increased risk of lung cancer mortality (94, 95). Red meat contains high amount of saturated
fat. The previous findings lent support to the view that high intake of saturated fat may be
linked to poor lung cancer survival. Previous studies observed an unfavorable effect of diets
with high saturated fat on the prognosis of different types of cancer, including breast and
prostate cancers (167-170). Increased saturated fat intake may promote tumorigenesis by
altering inflammatory responses and oxidative stress (171). A cohort study of Swedish men
showed that high intake of saturated fat increased the risk of prostate cancer death among
patients with localized prostate cancer, whereas the association was not present among patients
with advanced disease (170). The identified association was consistent with the findings of this
dissertation, suggesting that stage of cancer could influence the association between saturated
fat intake and cancer prognosis. Interestingly, this study also showed a poor outcome for earlystage patients with obesity. Excess weight and saturated fat intake may accumulate energy
stored in adipose tissue, which promotes the release of inflammatory mediators resulting in the
increase of oxidative stress and chronic inflammation (172). Oxidative stress and chronic
inflammation are closely related to cancer development and progression (119). However, an
improved survival for high intake of saturated fat was observed in advanced-stage patients who
received primary chemotherapy. The excess fat intake is stored in adipose tissue that may
provide nutritional reserve to counterattack the damage made by treatment for advanced cancer
(173).
Most studies have focused attention to the relation of unsaturated fat intake with lung cancer
risk. To the best of my knowledge, this is the first cohort study to evaluate the association
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between unsaturated fat intake and lung cancer prognosis. The role of unsaturated fat in cancer
prognosis has been examined in breast, prostate and stomach cancers, but the findings were
inconsistent (99, 168, 169). This study found that high intake of monounsaturated fat was
associated with better overall survival among advanced-stage NSCLC patients who received
primary chemotherapy and were overweight. Monounsaturated fat intake is considered to have
an anti-inflammatory property, which may suppress tumorigenesis (174). As mentioned
earlier, patients with advanced-stage cancer may benefit from the metabolic reserves of body
fat to withstand treatment (173). Further research is needed to confirm the protective effect of
high intake of monounsaturated fat on this group of patients with advanced-stage NSCLC.
In Chapter IV, 2,339 NSCLC patients were divided into the discovery and the replication
sets to identify significant single nucleotide polymorphisms (SNPs) in fatty acid metabolism
genes that were associated with overall survival or recurrence. Those SNPs reaching statistical
significance in the discovery set were further examined in the replication set to select the
significant SNPs which have consistent associations in both datasets. This study identified four
SNPs that were associated with overall survival and one SNP was associated with recurrence
in NSCLC. These were novel SNPs and have not been found to be associated with cancer
prognosis previously. Among these SNPs, three SNPs in ACSL1, CYP2C8 and FADS2 were
predicted to be putatively functional, suggesting that they are candidates for further study.
ACSL1 plays a vital role in fatty acid synthesis and degradation. This study showed that
early-stage patients with a G variant rs4862417 were associated with 28% and 39% decreased
risk of death in the discovery and the replication sets, respectively. Variant rs2292899 in high
linkage disequilibrium (LD) to rs4862417 was predicted to have functional effects on
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transcriptional regulation through methylation. Erroneous methylation has been highly linked
to the development and progression of several cancers, including lung cancer (175). ACSL1
has been found to be lower expressed in lung cancer tissue that is associated with better survival
(176). Nevertheless, there has been no expression quantitative trait loci (eQTL) analysis
directly for rs4862417 nor its high LD SNPs, and thus further investigation is needed.
Both CYP2C8 and FADS2 regulate biosynthesis of unsaturated fatty acids from
polyunsaturated fatty acids. This study showed that early-stage patients with two G variants
CYP2C8:rs1934953 were associated with 42% decreased risk of death in the discovery set and
80% decreased risk in the replication set. rs1934953 was predicted to be located in the
transcription factor binding site for IRF2. IRF2 has been shown to inhibit cell proliferation and
migration in lung cancer (177), but how eQTL regulates expression of rs1934953 in lung tissue
is unknown and requires further research. In addition, this study found that early-stage patients
who carry a G variant FADS2:rs174611 were increased the risk of death by 28% in the
discovery set and 47% in the replication set. rs174611 was predicted to be located in the
transcription factor binding site for ELF1 that is an intermediate player involved in promoting
proliferation and migration in NSCLC through VEGF (178, 179). The expression of ELF1 has
been shown to be positively associated with VEGF (180). A direct eQTL regulating expression
of rs174611 showed that the number of risk alleles was correlated with increased FADS2
expression in lung tissue. These findings strongly support the unfavorable effect on survival
among early-stage NSCLC patients who carry the risk allele of rs174611. Moreover, the
association between rs174611 genotype and overall survival in early-stage NSCLC was
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modified by monounsaturated fat intake. A stronger unfavorable effect was observed in those
who had low intake of monounsaturated fat and carried the risk allele.

Strengths and Limitations
This is the first study that systematically investigates how dietary fat intake and SNPs in all
genes involved in fatty acid metabolism were correlated with overall survival and recurrence
in NSCLC patients. The role of fatty acids in clinical outcomes among patients with NSCLC
was prospectively examined. It is also the first study to examine the potential impact of dietary
fat intake on the association between genetic variants and overall survival among NSCLC
patients. This study used a previously validated food frequency questionnaire to collect dietary
fat intake and was able to adjust for potential confounding factors to minimize the possibility
of confounded associations. In addition, the sample size of this study was large, which gave
more reliable results with greater precision and power. However, there are also several
limitations to this study. First, the dietary information was based on self-reported data, and
study participants were asked to recall what they had eaten during the past year. Participants
may be unable to precisely recall the actual food they consumed, resulting in measurement
errors in dietary data. It is unlikely that the measurement error was the differential of clinical
outcomes. Second, the study participants only included non-Hispanic whites and external
validation was not available, and thus we should be cautious about extrapolating our findings.
Third, only a small proportion of patients had high intake of monounsaturated or
polyunsaturated fat, which indicated a lower precision and statistical power. Lastly, although
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this study adjusted for potential epidemiologic and clinical factors in the analysis, the
possibility of uncontrolled confounding factors may not be completely excluded.

Future Directions
This dissertation was motivated by a lack of evidence on the influence of fatty acids on lung
cancer prognosis. This dissertation utilized dietary, genetic and clinical data to explore how
dietary fat intake and genetic variants in fatty acid metabolism genes were linked with overall
survival and recurrence among patients with NSCLC. The results of this dissertation advance
knowledge to improve prognosis among patients with NSCLC.
The results of this dissertation indicated that dietary fat intake was associated with overall
survival among NSCLC patients, but the association seems to depend on the subtypes of fat,
clinical stage, and types of treatment. There was a decreased overall survival for early-stage
NSCLC patients with high intake of saturated fat. No similar patterns for total fat and other
subtypes of fat were found. By contrast, there was an increased overall survival for advancedstage NSCLC patients with primary chemotherapy who had high intake of saturated or
monounsaturated fat. Nevertheless, there was no evidence for the association between fat
intake and disease recurrence. This dissertation suggested that early-stage NSCLC patients
may need to reduce consumption of saturated fat, and those who have advanced-stage and
receive primary chemotherapy may need to get enough fat intake. Further studies are needed
to confirm these findings and elucidate the mechanisms underlying the effect of saturated and
monounsaturated fat intakes on lung cancer prognosis.
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In addition, the results of this dissertation supported the involvement of genetic variants in
fatty acid metabolism genes in overall survival, particularly for those with early-stage NSCLC.
Variants ACSL1:rs4862417, CYP2C8:rs1934953 and FADS2:rs174611were important SNPs
affecting survival among patients with early-stage NSCLC. These SNPs have not been
identified with NSCLC prognosis in the previous study, and none of them has taken dietary fat
intake into account. This study indicated a multiplicative interaction between an individual’s
genotype and habitual intake of monounsaturated fat that modulated the risk of survival in
early-stage NSCLC. This dissertation suggested that early-stage NSCLC patients with G allele
of rs174611 may need to increase the consumption of monounsaturated fat. More studies are
needed to clarify how dietary factors interact with genetic variants to modify the prognosis of
NSCLC.
Taken together, consuming fat in food and synthesizing fatty acids in human body both
influence overall survival and recurrence among NSCLC patients. A novel gene-diet
interaction with monounsaturated fat intake for NSCLC survival highlighted that diet may
modify the effect of genetic variants on disease prognosis, which would be a key to achieving
better patient care. However, in the absence of evidence supporting our findings, more studies
across populations and solid experimental approaches will provide insights into the
mechanisms underlying the association. This knowledge will contribute to better geneticallytargeted nutrition advice to the public regarding NSCLC prognosis in the future.
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APPENDICES
Appendix A: List of 94 fatty acid metabolism genes (691 SNPs) for this study
Gene

Gene full name

Chr

Start
Position

End
position

No. of
SNPs

ACADM
ACOT7
CPT2

acyl-CoA dehydrogenase medium chain
acyl-CoA thioesterase 7
carnitine palmitoyltransferase 2
cytochrome P450 family 2 subfamily J
member 2
cytochrome P450 family 4 subfamily A
member 11
cytochrome P450 family 4 subfamily A
member 22
ELOVL fatty acid elongase 1
mitochondrial trans-2-enoyl-CoA
reductase
phospholipase A2 group IVA
palmitoyl-protein thioesterase 1
prostaglandin-endoperoxide synthase 2
sterol carrier protein 2
thioesterase superfamily member 4
thioesterase superfamily member 5
acyl-CoA dehydrogenase long chain
acyl-CoA synthetase long chain family
member 3
hydroxyacyl-CoA dehydrogenase
trifunctional multienzyme complex
subunit alpha
hydroxyacyl-CoA dehydrogenase
trifunctional multienzyme complex
subunit beta
acetyl-CoA acyltransferase 1
enoyl-CoA hydratase and 3-hydroxyacyl
CoA dehydrogenase
glutathione peroxidase 1
acyl-CoA oxidase 3
acyl-CoA synthetase long chain family
member 1
cytochrome P450 family 2 subfamily U
member 1
ELOVL fatty acid elongase 6
hydroxyacyl-CoA dehydrogenase
hematopoietic prostaglandin D synthase
stearoyl-CoA desaturase 5
acyl-CoA synthetase long chain family
member 6
ELOVL fatty acid elongase 7
hydroxysteroid 17-beta dehydrogenase 4
leukotriene C4 synthase

1
1
1

75962870
6246919
53434689

76001771
6376413
53452455

4
10
5

1

60131568

60165011

5

1

47167433

47180004

1

1

47375694

47387113

2

1

43601659

43606286

2

1

29391972

29430041

4

1
1
1
1
1
1
2

1.85E+08
40310969
1.85E+08
53165536
1.5E+08
1.5E+08
2.11E+08

1.85E+08
40335555
1.85E+08
53289870
1.5E+08
1.5E+08
2.11E+08

23
6
2
7
2
4
2

2

2.23E+08

2.24E+08

11

2

26267008

26321098

6

2

26321120

26366837

3

3

38139211

38153619

5

3

1.86E+08

1.86E+08

7

3
4

49369613
8418909

49370795
8493352

1
13

4

1.86E+08

1.86E+08

12

4

1.09E+08

1.09E+08

4

4
4
4
4

1.11E+08
1.09E+08
95438730
83769714

1.11E+08
1.09E+08
95483050
83939034

23
3
6
37

5

1.31E+08

1.31E+08

9

5
5
5

60083373
1.19E+08
1.79E+08

60175858
1.19E+08
1.79E+08

13
9
1

CYP2J2
CYP4A11
CYP4A22
ELOVL1
MECR
PLA2G4A
PPT1
PTGS2
SCP2
THEM4
THEM5
ACADL
ACSL3
HADHA

HADHB
ACAA1
EHHADH
GPX1
ACOX3
ACSL1
CYP2U1
ELOVL6
HADH
HPGDS
SCD5
ACSL6
ELOVL7
HSD17B4
LTC4S
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ACAT2
ECI2
ELOVL2
ELOVL4
ELOVL5
PPT2
TBXAS1
EPHX2
PTGDS
PTGES
PTGES2
PTGS1
ACSL5
AKR1C3
ALOX5
CYP2C19
CYP2C8
CYP2C9
ECHS1
ELOVL3
GPAM
OLAH
SCD
CPT1A
FADS1
FADS2
HSD17B12
ACACB
ACADS
LTA4H
PTGES3
ACOT4
GPX2
ACSBG1
CYP1A2
ECI1
ACACA
ACADVL
ACOX1
ALDH3A2
ALOX12
ALOX12B
ALOX15

acetyl-CoA acetyltransferase 2
enoyl-CoA delta isomerase 2
ELOVL fatty acid elongase 2
ELOVL fatty acid elongase 4
ELOVL fatty acid elongase 5
palmitoyl-protein thioesterase 2
thromboxane A synthase 1
epoxide hydrolase 2
prostaglandin D2 synthase
prostaglandin E synthase
prostaglandin E synthase 2
prostaglandin-endoperoxide synthase 1
acyl-CoA synthetase long chain family
member 5
aldo-keto reductase family 1 member C3
arachidonate 5-lipoxygenase
cytochrome P450 family 2 subfamily C
member 19
cytochrome P450 family 2 subfamily C
member 8
cytochrome P450 family 2 subfamily C
member 9
enoyl-CoA hydratase, short chain 1
ELOVL fatty acid elongase 3
glycerol-3-phosphate acyltransferase,
mitochondrial
oleoyl-ACP hydrolase
stearoyl-CoA desaturase
carnitine palmitoyltransferase 1A
fatty acid desaturase 1
fatty acid desaturase 2
hydroxysteroid 17-beta dehydrogenase 12
acetyl-CoA carboxylase beta
acyl-CoA dehydrogenase short chain
leukotriene A4 hydrolase
prostaglandin E synthase 3
acyl-CoA thioesterase 4
glutathione peroxidase 2
acyl-CoA synthetase bubblegum family
member 1
cytochrome P450 family 1 subfamily A
member 2
enoyl-CoA delta isomerase 1
acetyl-CoA carboxylase alpha
acyl-CoA dehydrogenase very long chain
acyl-CoA oxidase 1
aldehyde dehydrogenase 3 family member
A2
arachidonate 12-lipoxygenase, 12S type
arachidonate 12-lipoxygenase, 12R type
arachidonate 15-lipoxygenase
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6
6
6
6
6
6
7
8
9
9
9
9

1.6E+08
4060926
11088978
80681248
53240155
32229279
1.39E+08
27404562
1.39E+08
1.32E+08
1.3E+08
1.24E+08

1.6E+08
4080830
11152610
80713941
53321901
32239430
1.39E+08
27458403
1.39E+08
1.32E+08
1.3E+08
1.24E+08

3
6
6
4
9
4
30
10
2
5
3
10

10

1.14E+08

1.14E+08

9

10
10

5126568
45189635

5139878
45261571

4
10

10

96512453

96602661

7

10

96786519

96819244

7

10

96688430

96739137

13

10
10

1.35E+08
1.04E+08

1.35E+08
1.04E+08

1
2

10

1.14E+08

1.14E+08

5

10
10
11
11
11
11
12
12
12
12
14
14

15125951
1.02E+08
68278664
61323679
61352289
43658719
1.08E+08
1.2E+08
94918742
55343649
73128163
64475625

15155857
1.02E+08
68365881
61340886
61391401
43834745
1.08E+08
1.2E+08
94953496
55368156
73132223
64479284

7
7
12
5
11
12
28
2
14
2
2
6

15

76250242

76313954

15

15

72828237

72835994

2

16
17
17
17

2229897
32516040
7063877
71449183

2241604
32841015
7069309
71487039

3
17
2
7

17

19492656

19521500

4

17
17
17

6840108
7916679
4480963

6854779
7931746
4491709

5
9
3

ALOX15B
FASN
ACAA2
ACSBG2
CYP2B6
CYP4F2
CYP4F3
CYP4F8
TECR
PTGIS
CBR1
CPT1B
GGT1
GGT5
MCAT
ACSL4

arachidonate 15-lipoxygenase type B
fatty acid synthase
acetyl-CoA acyltransferase 2
acyl-CoA synthetase bubblegum family
member 2
cytochrome P450 family 2 subfamily B
member 6
cytochrome P450 family 4 subfamily F
member 2
cytochrome P450 family 4 subfamily F
member 3
cytochrome P450 family 4 subfamily F
member 8
trans-2,3-enoyl-CoA reductase
prostaglandin I2 synthase
carbonyl reductase 1
carnitine palmitoyltransferase 1B
gamma-glutamyltransferase 1
gamma-glutamyltransferase 5
malonyl-CoA-acyl carrier protein
transacylase
acyl-CoA synthetase long chain family
member 4
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17
17
18

7883083
77629503
45563873

7893177
77649395
45593900

7
2
4

19

6086710

6144112

6

19

46189044

46216141

6

19

15849834

15869884

5

19

15612707

15632570

5

19

15587029

15601448

7

19
20
21
22
22
22

14501382
47553818
36364155
49354156
23309718
22945622

14537792
47618114
36367332
49363862
23354972
22971110

7
6
3
10
2
5

22

41858156

41869347

5

23

1.09E+08

1.09E+08

3
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